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Insulin-like signaling is an important and conserved physiological regulator of growth 
and metabolism in multicellular animals. In humans, disturbance in insulin sensitivity 
leads to impaired clearance of glucose from the blood stream, due to less glucose 
uptake by liver and fat and other tissues, which is a hallmark of diabetes.  
 
While the core components of insulin-like pathway have been well established, the 
mechanisms that adjust insulin responsiveness are only known to a limited extent. A 
genetic screen in Drosophila that was designed to identify regulators of cellular 
insulin sensitivity in an in vivo context was done in our lab. This screen identified 
kinase suppressor of ras (ksr), an essential scaffold protein involved in MAPK/ERK 
signaling, as an enhancer of FoxO overexpression phenotype. Based on this screen, 
surprisingly, I discovered cross-talk between the epidermal growth factor receptor 
(EGFR)-activated MAPK/ERK and insulin-like signaling pathways. Cellular insulin 
resistance observed was due to downregulation of insulin-like receptor (inr) gene 
expression following persistent MAPK/ERK inhibition. The MAPK/ERK pathway 
regulates inr expression via the ETS-1 transcription factor Pointed. This regulation 
permits physiological adjustment of insulin sensitivity and subsequent maintenance of 
circulating glucose at appropriate levels, as failure of this regulation in the fat body 
leads to elevated circulating glucose levels, likely reflecting impaired clearance of 
dietary glucose from the circulation by the fat body.  
 
Overall, I provide evidence for a regulatory feed-forward mechanism through PI3K 
and InR that allows for dynamic transient responsiveness as well as more stable, long 
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lasting modulation of insulin responsiveness by growth factor receptor signaling. The 
combination of MAPK/ERK and insulin-like signaling pathways may contribute to 
robustness, allowing metabolism to be appropriately responsive to physiological 
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1.1 Insulin-like signaling pathway 
Insulin-like signaling pathway is a highly conserved regulatory network coordinating 
animal growth and metabolism with nutritional status (Taguchi & White 2008). Signal 
input of the pathway comprises insulin and insulin-like growth factors (IGFs) in 
mammals and insulin-like peptides (ILPs) in Drosophila. Sensing these different 
nutrients by their respective receptors activates the phophatidylinositol-3-kinase 
(PI3K)/AKT signaling pathway , which regulates a variety of downstream effectors, 
including the protein kinase TOR (target of rapamycin) and the FoxO (forkhead box 
class “O”) transcription factors, to adjust the cellular growth and metabolic 
hemeostasis at multiple levels.   
 
1.1.1 The phosphatidylinositol-3-kinase (PI3K)/AKT Pathway  
Signaling relay through the insulin/IGF pathway commences upon binding of the 
nutrient ligands to their receptors (Teleman 2010). In mammals, energy metabolism is 
regulated by insulin and tissue growth by IGFs, through their respective receptors 
(Cantley et al 2007). In Drosophila, there are seven ILPs, termed ILP1-7 (Figure 1.1.1, 
Page 3) (Zhang et al 2009), which are homologues of the mammalian insulin and 
IGFs (Brogiolo et al 2001; Sajid et al 2011). Overexpression of any of the seven ILPs 
during larval development is sufficient to drive an increase in body size (Ikeya et al 
2002), indicating that all seven ILPs are able to activate the receptor. However, 
functions of the seven ILPs seem not overlapping since each ILP has a distinct 
expression pattern and unique regulation (Broughton et al 2008). In particular, ILP 1, 
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2, 3 and 5 are expressed in specialized neurosecretory cells located in each brain 
hemisphere, called the insulin-producing cells (IPCs) (Cao & Brown 2001; Ikeya et al 
2002; Rulifson et al 2002), and ILP6 is expressed in the adipose tissue cells and is 
strongly induced during the wandering larval and pupal periods (Gronke et al 2010; 
Slaidina et al 2009). In spite of seven ligands, Drosophila only has one single insulin-
like receptor (InR), which is a receptor tyrosine kinase (RTK) and can be activated by 
mammalian insulin (Fernandez-Almonacid & Rosen 1987; Garofalo & Rosen 1988; 
Yenush et al 1996). The single InR mediates physiological responses related to both 
growth and metabolism (Hietakangas & Cohen 2009; Teleman 2010).  In sequence, it 
is similar to the mammalian insulin receptor, except that its C-terminus contains 400 
additional amino acids. This C-terminal extension contains three YXXM motifs 
similar to those found in mammalian Insulin Receptor Substrate 1 (IRS1) (Ogawa et 
al 1998), and enables Drosophila InR to bind downstream PI3K in the absence of an 
IRS (Chico, dreadlocks or Lnk in fly) (Ruan et al 1995; Slack et al 2010; Yenush et al 
1996). 
 
Functionally, InR stimulation by nutritional signals leads to the activation of the 
PI3K/AKT pathway (Figure 1.1.1, Page 3) (Perrimon 1994), one of the key effector 
pathways to mediate tissue growth (Kim et al 2004; Manning & Cantley 2007; 
Neufeld 2003). Upon InR auto-phosphorylation induced by ligands, the type I 
phosphatidylinostiol-3-kinae (PI3K) is recruited to the cell  membrane 
(Vanhaesebroeck et al 1997). Activated PI3K phosphorylates phosphatidylinositol-4, 
5-diphosphate (PIP2) on the plasma membrane and generates phophatidylinositol-
triphosphate (PIP3) (Engelman et al 2006; Oldham et al 2002). Molecular 
manipulation via expressing a membrane-tethered CAAX PI3K catalytic subunit  
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Figure 1.1.1 Core components of the insulin-like pathway in Drosophila. 
Functional connections between components are indicated. Black arrows indicate 
activation, whereas bar-ended lines indicate inhibitory interactions. Broken lines 
indicate indirect interactions or interactions requiring further study. Gray arrow 




(Dp110) activates it downstream in the absence of InR activation and causes tissue 
overgrowth in fly (Leevers et al 1996). Consistent with its role in tissue growth, 
hyperactivation of PI3K protein is quite often observed in various human cancers 
(Yuan & Cantley 2008). On the other hand, the lipid kinase activity of PI3K can be 
opposed by the phosphatase activity of PTEN, which is a tumor suppressor in human 
(Gao et al 2000; Goberdhan et al 1999; Huang et al 1999).  
 
The PI3K-produced accumulation of PIP3 on the membrane recruits two kinases 
PDK1 and AKT, via their lipid-binding PH (pleckstrin homology) domains (Franke 
2008), and results in the phosphorylation and activation of AKT by PDK1 (Alessi et 
al 1997). Additionally, activation of the pathway also leads to a second 
phosphorylation event on AKT by TOR complex 2 (TORC2) (Sarbassov et al 2005).  
As a protein kinase, AKT has a large number of downstream effectors involved in 
growth control and metabolism (Verdu et al 1999; Vereshchagina & Wilson 2006), 
including the TORC1 pathway through TSC2 and PRAS40 (Lobe in Drosophila) 
(Manning & Cantley 2007). AKT phosphorylates TSC2 and leads to the inhibition of 
the activity of TSC1/2 complex (Potter et al 2002). TSC1/2 complex acts as a GAP 
and inhibits the small GTPase Rheb (Garami et al 2003; Stocker et al 2003), which in 
turn activates TORC1 (Findlay et al 2005; Inoki et al 2002; Potter et al 2002). 
However, the physiological importance of this phosphorylation event on TSC2 by 
AKT remains unclear because a mutant TSC2 lacking the phosphorylation sites is 
able to fully rescue the loss of the wild type TSC2 gene, making the flies viable and 
normal body size (Dong & Pan 2004; Schleich & Teleman 2009). This suggests that 
probably in vivo the regulation of TSC2 by AKT is genetically redundant. Indeed, the 
Proline-rich AKT substrate 40 (PRAS40), a protein that directly interferes with 
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TORC1 binding to its substrate (Nascimento & Ouwens 2009), was found to be 
phosphorylated and prevented from binding TORC1 by AKT (Sancak et al 2007; 
Vander Haar et al 2007). This turns out to be a second mechanism trough which AKT 
regulates TORC1 activity. 
 
1.1.2 Two TOR Complexes 
The protein kinase TOR (Target of Rapamycin) exists in two complexes, with some 
components that are shared and some that are unique. TORC1 is the major rapamycin 
sensitive form of TOR (Rohde et al 2001). It is a very important mediator of growth 
control, metabolism and autophagy (Chang et al 2009; Rusten et al 2004; Scott et al 
2007; Scott et al 2004). The second complex, TOR complex 2 (TORC2), is insensitive 
to the inhibitory effects of rapamycin and phosphorylates substrates different from 
those by TORC1 (Hietakangas & Cohen 2009). A recent study showed that TORC2 is 
playing a modulatory role in the insulin-like signaling through the phosphorylation 
event on AKT (Hietakangas & Cohen 2007).  
 
1.1.2.1 TORC1 
TOR complex 1 (TORC1) consists of the Ser/Thr kinase TOR, the scaffolding protein 
regulatory-associated protein of TOR (Raptor) and lethal with Sec13 protein 8 (LST8) 
(Mendoza et al 2011). It was first identified in yeast and subsequently in other 
organisms including mammals (Heitman et al 1991). Genetic studies from multiple 
models have shown that manipulation of TORC1 activity results in significant 
changes in cell and tissue size (Teleman 2010). In the same way, TORC1 loss-of-
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function in Drosophila reduces tissue size by reducing cell size and cell number, 
whereas gain-of-function leads to opposite effects (Oldham et al 2000; Zhang et al 
2000). In addition, mild impairment of TORC1 activity in the whole larva results in 
reduced circulating glucose levels, as well as decreased lipid stores in adipose tissue 
(Luong et al 2006).  
 
Mechanistically, one of the main cellular processes that TORC1 regulates is protein 
translation (Lasko & Sonenberg 2007). This at least occurs at two levels: ribosome 
biogenesis, and translation initiation and elongation (Gingras et al 2001; Inoki & 
Guan 2006; Wei et al 2009). In mammals, TORC1 activity promotes ribosome 
biogenesis through two transcription factors involved in ribosomal RNAs (rRNAs) 
synthesis. The two transcription factors, TIF-IA (transcriptional intermediary factor-
IA) and UBF (upstream binding transcription factor), are regulated by TORC1 to 
interact with SL-1 (selectivity factor complex), which is required for RNA 
polymerase I mediated expression of rRNA (Grewal et al 2007; Hannan et al 2003; 
Mayer et al 2004). In Drosophila, TORC1 also regulates TIF-IA but not UBF, 
probably because the latter does not have an obvious homologue in fly. Instead, 
TORC1 regulates Myc, a growth effector downstream of MAPK signaling (Prober & 
Edgar 2002), through an unclear mechanism. Inhibition of TORC1 activity leads to 
rapid reduction in Myc protein level, and consequently in the expression of genes 
involved in ribosome biogenesis (Demontis & Perrimon 2009; Grewal et al 2005; 
Teleman et al 2008).  
 
Besides ribosome biogenesis, there are other two well-established substrates of 
TORC1 involved in the initiation of cap-dependent translation of mRNAs: they are 
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the eukaryotic initiation factor 4E binding protein (4E-BP) and ribosomal protein S6 
kinase (S6K) (Tee & Blenis 2005). Unphosphorylated 4E-BP binds to the eukaryotic 
initiation factor 4E (eIF4E) (Pause et al 1994) and blocks recruitment of the ribosome 
to the 5’ end of mRNAs (Hay & Sonenberg 2004). TORC1-mediated phosphorylation 
on 4E-BP leads to its dissociation from eIF4E, allowing the association of eIF4E with 
eIF4G and assembly of the translation preinitiation complex. Furthermore, TORC1 
also phosphorylates S6K at its ‘hydrophobic motif’ site, which allows S6K to be fully 
activated by PDK1 (Radimerski et al 2002; Rintelen et al 2001). Activated S6K then 
phosphorylates 40S ribosomal protein S6 (Bhaskar & Hay 2007; Hay & Sonenberg 
2004; Miron et al 2003; Wullschleger et al 2006). Despite their importance in this 
molecular context, flies lacking either 4E-BP or S6K are viable: 4E-BP mutants do 
not display any growth abnormality, but rather have some metabolic defects (Teleman 
et al 2005a); deficiencies in S6K exhibit a strong developmental delay and a severe 
reduction in body size, but much milder than TORC1 mutants (Montagne et al 1999).  
 
1.1.2.2 TORC2 
Compared to TORC1, less is known about the in vivo role of TORC2, which contains 
at least two essential members, the rapamycin-insensitive companion of TOR (Rictor), 
as well as stress-activated protein kinase interacting protein 1 (Sin1) (Hietakangas & 
Cohen 2007). Recent studies on TORC2 have provided a new insight into the insulin-
like signaling pathway (Dentin et al 2007), which now can be considered to comprise 
core components essentials for signal propagation and modulatory components that 
adjust the sensitivity and dynamic range of the pathway (Hietakangas & Cohen 2009). 
As mentioned above, phosphorylation of AKT on the PDK1 site is essential for its 
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ability to promote tissue growth, whereas TORC2-mediated phosphorylation is 
dispensable and only needed to reach the full spectrum of AKT substrates (Shiota et al 
2006; Yang et al 2006a). To support this, evidence from Drosophila showed that 
removal of TORC2 activity by mutation of Rictor only resulted in mild growth 
impairment and no observable metabolic defect (Hietakangas & Cohen 2007). In fact, 
fly TORC2 is needed to allow the high-level activation of AKT required to promote 
tissue growth under conditions when the pathway is hyperactivated, such as in the 
absence of PTEN (Hietakangas & Cohen 2009). Additionally, other studies in yeast 
and mammalian cells have also implicated TORC2 in regulating actin cytoskeleton 
(Jacinto et al 2004; Loewith et al 2002; Sarbassov et al 2004). Therefore, it will be 
interesting to further investigate if this regulation is also related to the insulin-like 
signaling pathway.  
 
1.1.3 The transcription factor FoxO (Forkhead box “O”) 
Like many other canonical pathways, the insulin-like signaling pathway also has 
principle downstream transcription factors, FoxOs, which has a profound impact on 
cell proliferation, growth control, animal metabolism and stress resistance (Gershman 
et al 2007; Gross et al 2008; Kramer et al 2008; Mattila et al 2009). FoxO 
transcription factors include four members (FoxO1, FoxO3a, FoxO4 and FoxO6) in 
mammals and a single protein in flies. All of them share a conserved 100-residue 
DNA binding domain, the so called forkhead domain (Huang & Tindall 2007).  
 
Evidence was accumulated that FoxO is emerging as a nodal point of crosstalk 
between various biological processes. Among them is the AKT-mediated nuclear 
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localization of FoxO by nutritional signals. As discussed above, PI3K-generated PIP3 
serves as a second message and recruits AKT to the membrane, where it is activated 
by phosphorylation. As a result, AKT phosphorylates FoxO on three conserved sites 
(Greer & Brunet 2005; Huang & Tindall 2007; Nielsen et al 2008), which leads FoxO 
to bind to 14-3-3 protein and retains it in the cytoplasm (Brunet et al 1999; Puig et al 
2003). This prevents FoxO from activating gene expression in response to insulin 
stimulation and promotes its ubiquitin-mediated proteasomal degradation (Matsuzaki 
et al 2003).  
 
In Drosophila, nevertheless, FoxO loss-of-function mutants do not show any growth 
phenotype under normal condition. In contrast, studies of FoxO gain-of-function 
suggest that the influence of FoxO appears to be context-dependent. Targeted 
overexpression of FoxO in eyes or wings reduced tissue size by reducing cell number 
(Junger et al 2003; Puig et al 2003). FoxO overexpression in fat body, Drosophila 
equivalent of liver and adipose tissue, extended life span (Giannakou et al 2004; 
Hwangbo et al 2004). This indicates a link of FoxO function to metabolism. Indeed, a 
study of the scaffolding protein, Melt, which modulates the ability of AKT to inhibit 
FoxO, showed that elevated FoxO activity reduced total body lipid levels (Teleman et 
al 2005b).  
 
These effects of Drosophila FoxO are mainly dependent on its large number of 
transcriptional targets (Figure 1.1.1, Page 3 and Figure 1.1.2, Page 12). The 
translational repressor 4E-BP is a direct target of FoxO (Junger et al 2003; Puig et al 
2003), and is also post-translationally regulated by TORC1 as discussed above 
(Wessells et al 2009). Physiologically, 4E-BP contributes a lot to the output of FoxO 
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(Zid et al 2009). Both FoxO and 4E-BP, for example, delay muscle functional decay 
and extend life span (Demontis & Perrimon 2010). In addition, FoxO was also found 
to directly bind to myc promoter and regulate myc expression (Teleman et al 2008). 
Similar to 4E-BP, Myc is mediated by TORC1 as well (Page 6), but positively in 
general. However, the regulation of myc by FoxO appears to be tissue dependent. 
FoxO is needed to maintain myc expression in fat body during starvation, while in 
muscle, FoxO negatively regulates myc activity (Demontis & Perrimon 2009). This 
tissue specific mediation during starvation seems to be related to the physiological 
functions of the two tissues, as muscle is considered to consume energy, but fat body 
is an energy supplier (Hietakangas & Cohen 2009). Furthermore, FoxO regulates 
lipase 4 transcriptionally both in vitro and in vivo, and acts as a key modulator of lipid 
metabolism, which may explain the reduced lipid level caused by elevated FoxO 
activity (Vihervaara & Puig 2008). Last, it was indicated that ILP2 expression in the 
IPCs is under the control of FoxO (Wang et al 2005). The mechanism of this FoxO-
dependent suppression of ILP2 is still unclear, but it provides an indication of the role 
of FoxO in systemic growth control (Hwangbo et al 2004).  
 
In agreement with the functional output of Drosophila FoxO, mammalian FoxOs 
activate a number of targets involved in cell proliferation and metabolism as well 
(Greer & Brunet 2005). FoxO3a, for instance, stimulates Growth arrest and DNA 
damage-inducible protein 45 (GADD45) to induce G2 arrest and DNA repair (Tran et 
al 2002). FoxO3a also initiates apoptosis by activating the pro-apoptotic Bcl-2 family 
member Bim (Sunters et al 2003). Moreover, targets of FoxO1, such as Glucose-6-
phosphatase (Nakae et al 2001b) and Pyruvate dehydrogenase kinase 4 (PDK4) 
(Furuyama et al 2003), are metabolism related.  
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1.1.4 Negative feedback regulation 
The insulin-like signaling pathway is well tuned to be stable enough so that it can 
function properly in a wide range of environmental challenges, especially when facing 
a complicated nutritional signaling network. In order to be robust, the pathway has 
developed a system of self-correcting and balancing. This occurs mainly through 
negative feedback loops, which tend to reduce the input signal that causes them.  
 
Two well established feedback regulations are taken as examples here (Figure 1.1.2, 
Page 12). First, activation of the insulin-like pathway leads to the activation of PDK1 
and TORC1, both of which phosphorylate and activate S6K (Rintelen et al 2001; 
Yang et al 2006b; Zhang et al 2000).  In mammals, S6K directly phosphorylates IRS1, 
the upstream of PDK1 and TORC1, and inhibits the recruitment of IRS1 to the 
activated InR (Harrington et al 2004). This regulation attenuates the sensitivity of 
PI3K/AKT pathway activation by the InR. As a result, reducing S6K phosphorylation 
increases signaling through AKT and TORC1, and therefore increases phosphorylaton 
of remaining TORC1 targets, including S6K itself. Although it is not well known 
whether this mechanism is also conserved in Drosophila or not, it was reported that 
depletion of S6K by RNAi in Drosophila S2 cell culture led to increased TORC2-
mediated phosphorylation on AKT after insulin stimulation (Yang et al 2006b). This 
at least indicates that in Drosophila S6K can reduce the input signal at or above AKT 
level. 
 
The second negative feedback loop involves the transcription factor FoxO (Marr et al 
2007) . It takes place when activation of the insulin-like pathway leads to the 
activation of AKT and consequently the inhibition of FoxO. In mammals, FoxO1 was 
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Figure 1.1.2 Negative feedback loops of insulin-like signaling. 
Prolonged activation of TORC1 leads to reduced PI3K/AKT signaling through S6K-
mediated inhibition of IRS. Low InR activation promotes high FoxO activity and 
consequently inr transcription, making the cells more sensitive to changes in 
nutritional environment. Gray line indicates the mechanism of the similar interaction 
in Drosophila is unknown. Events in red box indicate regulations via protein 




found to bind the promoter regions of both insulin receptor and Insulin Receptor 
Substrate 2 (IRS2) and activate their transcripts (Puig & Tjian 2005). In the same way, 
Drosophila inr is transcriptionally regulated by the single fly FoxO protein as well. It 
was shown that fly FoxO was able to recognize a 1562 bp fragment of the inr 
promoter and activated a luciferase reporter having this fragment (Puig et al 2003). 
Thus, InR activating signaling results in its own transcript down-regulation. 
Conversely, low insulin signaling, such as in a fasting condition, increases the 
transcription level of inr, sensitizing the system to renewed nutritional signal when 
nutrient conditions changed.  
 
1.1.5 Metabolism 
In the past decades, the role of the insulin-like signaling pathway in growth control, 
particularly in tumorigenesis, attracts more attention than its role in organismal and 
cellular metabolism. Now, however, the field of metabolism has been sparked by the 
emerging of world-wide epidemic of metabolic syndrome, such as type-2 diabetes and 
obesity (Hadjadj et al 2008; Ng 2008; van Raalte et al 2009). Actually growth and 
metabolism should not be separated and they are the two sides of a coin. The coin 
indeed is the insulin-like signaling pathway.  
 
Since components of the insulin-like signaling pathway are highly conserved from 
mammals to Drosophila, it is no surprise that the metabolic regulation of flies and 
humans have so much in common (Baker & Thummel 2007). By going through the 
cascade of the pathway, some metabolic studies have been mentioned in above 
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sections (Page 6, 7 and 9). Besides, there is one recent study (Broughton et al 2005) 
that is quite interesting in itself and is related to this work.  
 
The study was based on observations from flies with compromised production of ILPs 
resulting from genetic ablation of the IPCs. The Drosophila specific proapoptotic 
gene reaper (rpr) (McCarthy & Dixit 1998) was driven by a fragment of the ilp2 
promoter (Ikeya et al 2002) and the expression of ilp2, 3 and 5 was targeted disrupted 
by cell ablation. As a result, hypomorph of ilps was created, mimicking the reduction 
of insulin-like signaling activity. Two types of circulating sugar in insect hemolymph 
were checked: glucose, which is obtained from the diet (Jacobs 1968; Krasney et al 
1990; Kreneisz et al 2010), and trehalose, which is used as a homeostatic molecule 
that originates from the fat body and is used to distribute sugar to peripheral tissues 
(Becker et al 1996; Chyb et al 2003; Isabel et al 2005). IPC-ablated flies showed 
significant elevation of glucose, whereas trehalose was slightly lower compared to 
controls. In mammals, reduced insulin signaling is already known to be associated 
with diabetes, characterized by high blood glucose (Koopmans et al 1997; Rahaghi & 
Gough 2008). Taken together, this is suggestive that the insulin-like pathway is 
important to maintain systemic glucose homeostasis. This is consistent with the 
findings present in this work that insulin resistance due to downregulation of insulin-
like receptor gene expression impairs clearance of dietary glucose from the circulation. 
 




Mitogen-activated protein kinase (MAPK) pathways are involved in a broad spectrum 
of biological processes (Almog & Naor 2010; Aoki et al 2008; Bardwell 2006; 
Bluthgen & Legewie 2008; Boldt & Kolch 2004; Bradham & McClay 2006; Brown & 
Sacks 2008; Castoria et al 2008; Cuschieri & Maier 2005). MAPK pathways consist 
of an initial GTPase-regulated kinase (MAPKKK) that phosphorylates and activates 
an intermediate kinase (MAPKK) that, in turn, phosphorylates and activates an 
effector kinase (MAPK) (Mendoza et al 2011). In mammals, five molecularly distinct 
MAPK modules, each with specific biological roles, have been identified (Schaeffer 
& Weber 1999). Among these stands the extracellular signal-regulated kinase (ERK) 
pathway, which plays important roles in control of cell proliferation, cell 
differentiation and cell survival (Pearson et al 2001; Shaul & Seger 2007; Torii et al 
2004; Widmann et al 1999) in response to extracellular stimuli, such as activation of 
epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR) 
or vascular endothelial growth factor receptor (VEGFR) (Margolis & Skolnik 1994). 
 
1.2.1 The extracellular signal-regulated kinase (ERK) pathway 
The ERK pathway is a linear kinase cascade, evolutionarily conserved from 
Drosophila to mammals (Brzezianska & Pastuszak-Lewandoska 2011; Cakir & 
Grossman 2009; Corcelle et al 2007; Khavari & Rinn 2007; McKay & Morrison 2007; 
Nishimoto & Nishida 2006; Rubinfeld & Seger 2004; 2005). The knowledge 
surrounding the activation of the ERK cascade has been mostly derived from work 
conducted on receptor tyrosine kinases (RTKs) (Claperon & Therrien 2007), such as 
EGFR or VEGFR. A major consequence following RTK activation by growth factors 
is guanosine triphosphate (GTP) loading of the small GTPase Ras (Mitin et al 2005). 
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When bound to GTP, Ras is active and stimulates its downstream targets. However, 
Ras itself has intrinsic GTPase activity, which can be activated by GTPase-activating 
proteins (GAPs), such as GAP1 in Drosophila (Gaul et al 1992), to attenuate its signal 
transduction. In opposition to this, activation of Ras occurs largely through guanine 
nucleotide exchange factors (GEFs), which catalyze the exchange of Ras-bound GDP 
with free GTP (Buday & Downward 2008).  
 
Multiple downstream effectors are under Ras signaling, including the ERK module 
(Murphy & Blenis 2006) and the PI3K/AKT pathway (Prober & Edgar 2002) (Figure 
1.2, Page 18). The PI3K/AKT branch will be discussed in section 1.3 (Page 21). Ras 
protein controls the activity of MAPK/ERK by hierarchical phosphorylation events 
mediated by the MAPKKK Raf, which acts via a MAPKK called MEK. Each kinase 
phosphorylates and activates it downstream target, culminating in the activation of 
multiple targets including many transcription factors (Agell et al 2002; Crump 2002; 
Dhillon & Kolch 2002; Hagan et al 2006; Hilger et al 2002; Hood & Cheresh 2002; 
Kolch 2002; Kolch et al 2002; Lee & McCubrey 2002). Interestingly, a negative 
regulator of ERK signaling, Sprouty (Sty), was found to be transcriptionally induced 
by Ets-1 transcription factor (Pointed (Pnt) in Drosophila), a downstream 
transcription factor of ERK (Cabrita & Christofori 2003; Hacohen et al 1998; Kim & 
Bar-Sagi 2004; Li et al 2003; Mason et al 2006). This regulation enables the ERK 
pathway to negatively feedback on itself to keep its balance (Abou-Khalil & Brack 
2010; Guy et al 2009; Guy et al 2003; Kim & Bar-Sagi 2004; Tsang & Dawid 2004). 
However, Sprouty only specifically inhibits Ras-MAPK/ERK signaling by RTKs, like 
EGFR and FGFR (Casci et al 1999), leaving other MAPK pathways unaffected 
(Mason et al 2006). This specific inhibition on certain RTKs makes the point at which 
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Sprouty blocks MAPK/ERK activation remain controversial, as some work indicated 
the inhibitory effect maybe at the level of Raf (Yusoff et al 2002). 
 
1.2.2 Scaffold protein: Kinase Suppressor of Ras (KSR) 
In order to regulate the efficiency, location and duration of signal transmission, the 
MAPK/ERK pathway adopts specific scaffold proteins for its assembly (Bardwell 
2006; Kolch 2005; Machesky & Johnston 2007; Moscat et al 2007; Pullikuth & 
Catling 2007). As illustrated by recent studies conducted in Drosophila and mammals, 
Kinase Suppressor of Ras (KSR) was found to be such a protein regulating Ras-
mediated Raf activation (Claperon & Therrien 2007; Downward 1995) (Figure 1.2, 
Page 18).  
 
KSR protein was initially identified in Ras dependent genetic screen in Drosophila 
(Therrien et al 1995) and conserved in metazoans (Channavajhala et al 2003). Flies 
have a single ksr gene that is essential for viability. Clonal analysis of ksr loss-of-
function mutations showed cell proliferation and survival defects that were 
reminiscent of mutations in any positively regulative components of the ERK module 
(Therrien et al 1995). Evidence showed that KSR is a Raf-like pseudokinase, and 
functions as a scaffold protein, bridging Raf and MEK, which has been provided by 
its ability to associate independently with either protein in Drosophila S2 cells (Roy 
et al 2002). This scaffolding property of KSR is essential for ERK activation 
(Therrien et al 1996). Nevertheless, this is not the whole story, as genetic tests 
revealed that ksr heterozygous mutations were able to dominantly suppress the 
activity of RasV12, an active mutant of Ras (Buchanan et al 2005; Kortum et al 2006; 
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Figure 1.2 Crosstalk between MAPK/ERK pathway and PI3K/AKT signaling in 
Drosophila. 
MAPK/ERK module and PI3K/AKT pathway are under Ras signaling following 
receptor tyrosine kinases (RTKs, such as EGFR) activation. Ras protein controls the 
activity of ERK through kinases Raf and MEK. Each kinase phosphorylates and 
activates it downstream target, culminating in the activation of multiple targets 
including transcription factors Myc and Pnt. KSR functions as an essential scaffold 
protein bridging Raf and MEK. In addition, Ras is able to bind to PI3K and to 
promote its activity. This provides another way for Ras to regulate Myc through FoxO 




Sodhi et al 2001; Telang et al 2007; Vasseur et al 2003; Vidal et al 2002), but had no 
impact on a constitutively active Raf transgene (Therrien et al 1995). These 
observations suggested that KSR might also be acting between Ras and Raf, or in 
parallel to Raf. Indeed, further studies demonstrated that KSR was also part of a 
protein complex involving another scaffold protein, CNK, and its binding partner 
Hyphen/Aveugle to facilitate Raf activated by Ras (Claperon & Therrien 2007; 
Douziech et al 2006; Roignant et al 2006). To sum up, the functional analysis of KSR 
highlights the importance of efficient signal transduction from Raf to MEK and ERK 
(Claperon & Therrien 2007), as well as the molecular mechanism of regulating Ras-
mediated Raf activation (Anselmo et al 2002).   
 
1.2.3 Ets-1 transcription factor Pointed 
As an important downstream target of MAPK/ERK signaling, mammalian Ets-1 
shares a striking conservation with its fly counterpart Pointed (Pnt) (Hsu & Schulz 
2000). Slightly different from mammalian Ets-1, Drosophila pnt gene is expressed as 
two alternative splicing isoforms, P1 and P2, which share a C-terminal region that 
contains the ETS domain (O'Neill et al 1994). Experiments showed that activation of 
EGFR leads to the nucleus entry of ERK and phosphorylation of PntP2 at a single site 
(Brunner et al 1994). This post-translational modification allows the transcription 
factor to bind specifically to the DNA sequences having an invariant core motif 5′-
(C/G)(A/C/G)GGA(A/T)(A/G)-3′ (Rogers et al 2005; Wasylyk et al 1993).  
 
Genetic studies have revealed that Pointed is an important regulator of eye 
development, neurogenesis, tracheal cell migration and oogenesis (Gabay et al 1996; 
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Klambt 1993; Morimoto et al 1996; Rogers et al 2005; Rohrbaugh et al 2002; 
Wasylyk et al 1997; Yamada et al 2003; Zhu et al 2011). More interestingly, a recent 
publication reported that the TORC1 pathway was involved in temporal control of 
differentiation in a PntP2 dependent manner during Drosophila development 
(McNeill et al 2008). The study was based on the knowledge that activation of 
PI3K/AKT signalling mediating through TORC1 led to precocious differentiation of 
photoreceptors in fly eyes, while reduction of its activity delayed differentiation 
(Bateman & McNeill 2004). What was found by them (McNeill et al 2008) is that 
elevated PI3K pathway activity upon eye differentiation led to the up-regulation of 
Pointed expression, which is a well-known target during photoreceptor differentiation. 
This turns out to be a cross regulation from insulin-like signalling to MAPK/ERK 
pathway to coordinate cell growth and cell differentiation, although, as elucidated by 
the publication (McNeill et al 2008), this regulation is temporal and tissue specific.  
 
1.3 Crosstalk between insulin-like signaling and MAPK/ERK pathway 
Both insulin-like signaling and MAPK/ERK pathway are more or less modeled as 
linear signaling conduits activated by different stimuli. However, experiments are 
hinting that they might intersect to regulate each other and then co-regulate 
downstream functions (Cheskis et al 2008; Lehman & Gomez-Cambronero 2002; 
Mendoza et al 2011; Sakaue et al 1995; Schmidt et al 2009). Integration of the activity 
of the two cascades through crosstalk permits them to influence each other’s activity, 




As mentioned above (Page 6 and 10), Myc is regulated by TORC1 and FoxO in 
different means. In fact, Myc was first identified as an important growth effector 
downstream of Ras signaling in both mammalian cell culture and Drosophila 
(Okajima & Thorgeirsson 2000; Pintus et al 2002; Prober & Edgar 2002; Sears et al 
1999; Sears et al 2000; Tsuneoka & Mekada 2000). This could be taken as a second 
example for the cross regulatory loop from insulin-like signaling pathway to 
MAPK/ERK. More importantly, it should be noted in the same Myc study conducted 
in fly, and later in mammalian research, that Ras is able to bind to the catalytic 
subunit of PI3K (Dp110 in Drosophila) and to promote its activity (Pacold et al 2000; 
Prober & Edgar 2002; Rodriguez-Viciana et al 1994). The binding of Ras to PI3K is 
independent of its ability to activate the canonical downstream Raf (Jiang & Edgar 
2009). Physiological analysis using a mutant Dp110 form that cannot bind Ras 
showed that this interaction is dispensable for insulin-like signaling, but disruption of 
this interaction makes insulin-like pathway activity at low levels, leading to less egg 
production and slightly smaller flies (Orme et al 2006). This mechanism links the 
degree of Ras activation to a subtle modulation of PI3K activity and may be useful in 
a more dynamic regulatory context where input of growth factor signaling to Ras can 
promote responsiveness to insulin to achieve maximal PI3K/AKT signaling 
(Rodriguez-Viciana et al 1996).  
 
In comparison to this Ras-PI3K connection, the work reported here provides evidence 
for a second mechanism in Drosophila through which EGFR signaling via the 
MAPK/ERK pathway modulates the insulin-like pathway activity. This new 
regulatory mechanism acts via the ETS-1 transcription factor Pointed to regulate 
insulin-like receptor gene expression. As a result, InR levels are sensitive to both 
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2 Results  
 
2.1 kinase suppressor of ras (ksr) was identified as enhancer of FoxO gain-of-
function 
In order to identify novel regulators of the insulin-like signaling pathway, our former 
lab colleague Ville Hietakangas performed a genetic screen for modifiers of FoxO 
gain-of-function phenotype in the Drosophila eye. Since insulin-like signaling limits 
FoxO activity (Puig et al 2003), overexpression of FoxO challenges the regulatory 
capacity of the pathway, and creates a sensitized genetic background. In the eye, this 
produces small eye size associated with rough eye surface (Junger et al 2003; Puig et 
al 2003). As insulin-like signaling is a known regulator of growth, Ville focused on 
screening RNAi lines that had earlier shown tissue undergrowth in a wing-based 
screen (Genevet et al 2010) (Figure 2.1.1, Page 24). UAS-RNAi lines against ~200 
conserved genes were expressed under GMR-GAL4. One of the genes, whose 
downregulation enhanced the FoxO overexpression phenotype, was PI3K (Dp110, 
CG4141) (Weinkove et al 1997). This serves as a positive control of the screen, 
because activation of AKT signaling by PI3K is required for the insulin-like pathway 
to suppress FoxO activity (Willecke et al 2011). In addition, this screen also identified 
kinase suppressor of ras (ksr, CG2899). Depletion of KSR enhanced the FoxO 
phenotype (Figure 2.1.2A, Page 25), but on its own, did not show any obvious eye 
defect (Figure 2.4C and D, Page 33 and Figure 2.6.1B, Page 40). The lack of an 
obvious eye phenotype resulting from KSR depletion alone presumably reflects the 
magnitude of KSR downregulation generated with the GMR-GAL4 driver during the 
phase of eye imaginal disc growth. As an independent means to assess the specificity   
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Figure 2.1.1 Effect of depleting KSR, AKT or Raf on growth in the wing. 
UAS RNAi transgenes targeting AKT, KSR or Raf were expressed in the posterior 
compartment of the wing imaginal discs under control of engrailed-GAL4. 
Knockdown of MAPK/ERK pathway components lead to undergrowth similar to that 
caused by suppression of insulin-like signaling pathway. Upper panels: show 
photographs of the resulting adult wings. Red dots indicate the border between 
anterior and posterior compartments. Note the reduced area of the P compartment. 
Lower panels: higher magnification views showing individual cell size (each cell 





Figure 2.1.2 Effect of reduced ksr gene dosage on the FoxO overexpression 
phenotype. 
(A) Photomicrographs of adult eyes. Left panel: UAS-FoxO was expressed in the 
developing eye with the GMR-GAL4 driver. Middle and right panels: GMR-GAL4 + 
UAS-FoxO also expressing UAS-RNAi transgenes to deplete PI3K or KSR. 
(B) Upper panel: photographs of adult eyes. From left to right: GMR-GAL4 alone; 
GMR-GAL4 with one mutant copy of the ksr gene; GMR-GAL4 + UAS-FoxO; GMR-
GAL4 + UAS-FoxO with one mutant copy of the ksr gene. Lower panel: plot of total 
eye area measured in pixels from digital images using Image J. Error bars indicate 
standard deviation from measurement of at least 5 eyes for each genotype. (*) 






of the ksr RNAi effect, I tested the effect of removing one copy of ksr gene by an 
EMS allele (Karim et al 1996), and also found enhancement of the FoxO 
overexpression phenotype (Figure 2.1.2B, Page 25). Again, removing one copy of the 
ksr gene on its own did not reduce eye size, indicating the utility of the sensitized 
background to identify subtle modulators of pathway activity. 
 
To determine whether apoptosis contributes to the phenotype, I quantified the effects 
of expressing the apoptosis inhibitor p35 (Figure 2.1.3, Page 27). By itself p35 did not 
significantly affect eye size. When expressed together with GMR-FoxO, p35 caused a 
slight increase in eye size due to less cell apoptosis, but not enough to offset the 
reduction caused by FoxO overexpression. Likewise, coexpression of p35 with GMR-
FoxO and KSR-RNAi, rescued the reduction of eye size to some extent, but did not 
account for the enhancement of the GMR-FoxO phenotype caused by KSR-RNAi. 
Thus the effects of KSR depletion cannot be attributed solely to reduced cell viability.  
 
2.2 KSR regulates FoxO activity in an AKT-mediated manner 
FoxO protein is regulated at multiple levels, including nuclear localization (Huang & 
Tindall 2007). FoxO is constitutively nuclear in cells devoid of growth factors, but 
upon insulin stimulation FoxO is transported into cytoplasm through AKT-mediated 
phosphorylation. As expected, RNAi-mediated depletion of PI3K limited the insulin-
induced FoxO shift towards cytoplasm. Depletion of KSR by RNAi produced a 
similar effect (Figure 2.2.1A, representative images in Figure 2.2.1B, Page 28). 
Furthermore, depletion of KSR also led to nuclear accumulation of FoxO in the larval 
fat body (Figure 2.2.1C, Page 28), suggesting a possible link to energy metabolism.  
27 
 
Figure 2.1.3 Effect of suppressing apoptosis on the FoxO overexpression 
phenotype. 
Upper panel: adult eyes expressing GMR-GAL4 alone or with UAS-p35, with UAS-
FoxO or UAS-FoxO and UAS-RNAi-KSR. Lower panel: quantification of the total area 
of affected eyes of the indicated genotypes measured in pixels from digital images 
using Image J. Error bars indicate standard deviation from measurement of at least 5 
eyes for each genotype. (***) indicates that the reduction of eye area was significant, 
Student’s t-test: p<0.001. (N.S.) indicates that there was no significant effect of p35 in 




Figure 2.2.1 KSR regulates FoxO activity through its subcellular localization.  
(A) Quantification of the subcellular localization of transfected FoxO-GFP. S2 cells 
with GFP signal were classified into 3 groups according to FoxO localization (N: 
predominantly nuclear; CN: equal levels in cytoplasm and nucleus; C: predominantly 
cytoplasmic). Upper panels: compare unstimulated cells with cells stimulated with 
insulin (10 ug/ml, 30 min). Lower panels: cells transfected with dsRNA to deplete 
PI3K or KSR and after 4 days, stimulated with insulin. Error bars represent standard 
deviation from 3 independent experiments. At least 130 cells were checked in total for 
each treatment. Fisher’s exact test was used to assess the difference between insulin-
stimulated S2 cells with and without KSR depletion: (**) p<0.01; (***) p<0.001. 
(B) Representative images showing FoxO localization in S2 cells. Left panel: (N) 
predominantly nuclear. Middle panel: (CN) equal levels in cytoplasm and nucleus. 
Right panel: (C) predominantly cytoplasmic.  
(C) Left panels: immunofluorescent images of fat body dissected from wandering 3rd 
instar larvae stained with anti-FoxO (green). Nuclei were labeled with DAPI (blue). 
Larvae expressed UAS-RNAi-KSR under pumpless-GAL4 control. Pumpless is active 
in fat body as well as other tissues. Control larvae expressed GAL4 without the RNAi 
transgene. Right panel: quantification of the ratio between unclear FoxO and 
cytoplasmic FoxO in fat body expressing ppl-GAL4 or with UAS-RNAi-KSR. 
Subcellular regions were defined by DAPI staining. FoxO intensities were measured 
in pixels from digital images using Image J. Error bars represent standard deviation 






Then I asked whether the influence of KSR depletion acts via AKT or in a parallel 
pathway overriding AKT to mediate FoxO localization. To address this question, I 
monitored insulin-induced activation of AKT. Depletion of KSR suppressed insulin-
induced phosphorylation of the “hydrophobic motif” site S505 on AKT (Figure 
2.2.2A, Page 30), a molecular measurement of AKT activity (Hietakangas & Cohen 
2007). To test whether other downstream targets of AKT besides FoxO were affected, 
I analyzed phosphorylation of S6K, a target of TORC1 (Wullschleger et al 2006). 
Insulin-induced phosphorylation shifts some of the S6K protein into a ladder of 
slower migrating forms (Gao et al 2002). Depletion of KSR reduced the extent of the 
insulin-induced mobility shift of S6K (Figure 2.2.2B, Page 30). The effect of KSR 
depletion was similar to that of PI3K depletion, in line with the prediction of reduced 
TORC1 activation by AKT. These data suggest that depletion of KSR lowers the 
sensitivity of these cells to insulin stimulation.  
 
2.3 Roles of other MAPK pathway components 
The known functions of KSR are related to MAPK activation (Anselmo et al 2002; 
Roy et al 2002). To ask if the effects of KSR on insulin signaling are mediated via the 
canonical MAPK pathway, I tested RNAi-mediated depletion of other components of 
the pathway. Similar to ksr RNAi, depletion of D-MEK inhibited AKT 
phosphorylation (Figure 2.3A, Page 31). Moreover, AKT targets were also affected. 
For example, D-MEK depletion reduced phosphorylation of S6K (Figure 2.3B, Page 
31) and Raf depletion suppressed the cytoplasmic localization of FoxO in response to 
insulin (Figure 2.3C, Page 31). In sum, the effects of KSR on insulin signaling are 
likely to be due to inhibition of canonical ERK signaling. 
30 
 
Figure 2.2.2 KSR affects AKT and it downstream TORC1 activity. 
(A) Immnunoblots to visualize the level of AKT phosphorylation. Cells were treated 
with dsRNA to deplete KSR or PI3K and stimulated with insulin (“+”) or left 
untreated (“-“). AKT phosphorylation was visualized using an antibody specific for 
the phosphorylated form of the AKT ‘hydrophobic motif’ site S505. Antibody to total 
AKT protein and Kinesin were used as loading controls. Experiments were repeated 
for 5 times. 
(B) Immunoblot to visualize the level of S6K phosphorylation. Insulin-induced 
phosphorylation of S6K by TORC1 causes a mobility shift of S6K on SDS-PAGE. S2 
cells were treated as in (A). Samples were run on the same gel, but intervening lanes 

























Figure 2.3 MAPK/ERK pathway-mediated regulation of PI3K/AKT signaling. 
(A) Immunoblots to visualize the level of AKT S505 phosphorylation and total AKT 
in cells treated with dsRNA to deplete KSR, D-MEK or PI3K. Cells were stimulated 
with insulin (30 min). Samples were run on the same gel, but intervening lanes have 
been removed as indicated. 
(B) Immunoblot to visualize the level of S6K phosphorylation in cells treated with 
dsRNA to deplete D-MEK. Cells were stimulated with insulin (30 min). The slower 
migrating forms of S6K reflect phosphorylation by TORC1. 
(C) Charts showing quantification of the subcellular localization of a FoxO-GFP 
fusion protein, as in Figure 2.2.1 (Page 28). Cells were transfected with dsRNA to 
deplete Raf or left untreated and after 4 days stimulated with insulin (30 min). 
(D) Immunoblots to visualize the level of AKT and ERK phoshorylation in S2 cells 
treated with the MEK inhibitor U0126 or in control cells. Cells were treated with 
dsRNA to deplete PI3K, KSR or GFP as a control and after 5 days stimulated with 
insulin and treated with U0126 for 10 min as indicated. Pharmacological inhibition of 
MEK by U0126 was effective, as visualized by anti-P-ERK. Anti-Kinesin was used as 
loading control. Samples were run on the same gel, but intervening lanes have been 
removed as indicated.  
(E) Photomicrographs of adult eyes expressing GMR-GAL4 driver (upper panels) or 
GMR-GAL4 + UAS-FoxO (lower panels). The effects or removing one copy of the 
sprouty gene are shown in the panels labeled sty/+. Eye sizes are quantified in the 
chart on the right. (**) Student’s t-test <0.01. 
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Next, I tested whether acute pharmacological inhibition of the MAPK pathway would 
block AKT activation in response to insulin stimulation. This proved not to be the 
case: although the MEK inhibitor U0126 efficiently reduced phosphorylation of ERK, 
it had no impact on the insulin-induced phosphorylation of AKT (Figure 2.3D, Page 
31). This indicates that the influence of ERK signaling on AKT activation cannot be 
compromised by short-term (10 min) inhibition of MAPK pathway activity. The 
apparent requirement for long-term inhibition suggests that its influence is more likely 
through an indirect route, rather than through direct phosphorylation of an insulin 
pathway component by MEK or ERK. 
 
To confirm these cell-based observations in vivo I asked whether modulation of RTK-
regulated ERK signaling would modulate sensitivity to insulin-like signaling using the 
FoxO overexpression assay in the eye. Sprouty (Sty) is a negative regulator of ERK 
signaling, which is induced by activation of RTKs, such as EGFR and FGFR (Casci et 
al 1999; Hacohen et al 1998). Reducing the level of Sprouty activity is expected to 
strengthen RTK-induced ERK activity and consequently to increase insulin 
sensitivity. In line with this prediction, removing one copy of the sprouty gene 
significantly suppressed the FoxO phenotype in the eye (Figure 2.3E, Page 31). 
 
2.4 KSR acts upstream of PI3K 
Insulin-induced PI3K activation increases the level of the phosphoinositide PIP3, 
which leads to membrane recruitment of proteins with a pleckstrin-homology (PH) 
domain (Engelman et al 2006). This leads to AKT activation by PDK1 and TORC2. 
To assess PIP3 level, I used a GFP-linked pleckstrin homology (PH) domain from  
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Figure 2.4 KSR acts upstream of PI3K. 
(A) Visualization of the level PIP3 in the cell membrane by localization of a GFP-
GRP1 PH domain fusion protein. Upper panel: photomicrographs showing 
translocation of GFP-GRP1 PH to the membrane upon insulin stimulation. The ratio 
of membrane to cytoplasmic GFP levels was measured as pixel intensity along the 
white line. Lower panel: chart showing the ratio of membrane to cytoplasmic GFP 
levels. PI3K and KSR depleted cells showed less PH domain membrane localization 
upon insulin stimulation. (***) Student’s t-test<0.001. 
(B) Immunoblots to visualize the level of AKT and ERK phosphorylation in S2 cells 
transfected to express the membrane-tethered form of Dp110 CAAX compared to 
control cells transfected with the empty vector. Cells were cultured in serum-free 
medium and were not stimulated by addition of insulin. Upper to lower: antibody to 
phosphorylated S505 AKT; antibody to total AKT; Antibody to the phosphorylated 
form of ERK; antibody to the Myc epitope tag to visualize expression of the Dp110 
transgene. Samples were run on the same gel, but intervening lanes have been 
removed as indicated.  
(C) Adult eyes expressing GMR-GAL4 and UAS-FoxO, UAS-Dp110 CAAX and/or a 
UAS-RNAi-KSR transgene to deplete KSR. 
(D) Quantification of the total eye area measured in pixels from digital images using 
Image J. Error bars indicate standard deviation from measurement of at least 5 eyes 
for each genotype. Student’s t-test: (***) p <0.001. (N.S.) indicates that there was no 
















GRP1 protein (Britton et al 2002). Insulin treatment induced prominent membrane 
accumulation of the GRP1-PH domain, which was prevented by depletion of PI3K. 
Similarly, RNAi-mediated depletion of KSR reduced membrane localization of 
GRP1-PH in response to insulin (Figure 2.4A, Page 33). These observations suggest 
that KSR regulates insulin-like signaling at or above the level of PI3K. 
 
One possibility is that KSR regulates PI3K activity. Activation of PI3K in response to 
insulin involves localization of the catalytic subunit of PI3K, Dp110, to the 
membrane. PI3K could be activated without upstream input by targeting Dp110 to the 
membrane using a CAAX motif (Leevers et al 1996). If KSR acts independent of 
PI3K, or KSR enhances the kinase activity of PI3K independent of its membrane 
localization, I would expect a corresponding inhibition of the ability of Dp110 CAAX 
to induce AKT phosphorylation upon KSR depletion. On the other hand, if KSR acts 
upstream of PI3K, no influence on AKT phosphorylation would occur with this 
constitutively active form of PI3K in the absence of insulin stimulation. Depletion of 
KSR in S2 cells expressing Dp110 CAAX had no effect on AKT phosphorylation, 
although it effectively reduced MAPK pathway activity, measured by ERK 
phosphorylation (Roy et al 2002) (Figure 2.4B, Page 33). Consistently, in vivo this 
CAAX form of Dp110 made FoxO gain-of-function eyes insensitive to the 
enhancement caused by KSR RNAi (Figure 2.4C and D, Page 33).  These results 
suggest that silencing KSR is more likely to act upstream of PI3K rather than hamper 
PI3K from activating AKT. 
 
2.5 MAPK signaling regulates inr expression 
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The experiments with Dp110 CAAX suggested that the ERK pathway acts above the 
level of PI3K. I therefore sought to monitor InR expression level as well as activation, 
making use of a shift in its electrophoretic mobility that results from ligand-induced 
auto-phosphorylation (Figure 2.5.1A, lanes 1 and 4, Page 36). Surprisingly, I found 
that depletion of KSR led to a reduction in the level of total InR protein. This was 
observed in both insulin-treated and untreated cells. Depletion of PI3K did not 
produce a comparable effect, indicating that PI3K/AKT activity does not significantly 
feedback on InR protein levels. Thus the decrease in InR level appears to be a specific 
effect caused by dysfunction of MAPK pathway. Consistently, I found KSR depletion 
also led to a reduction of InR protein levels in the larval fat body (Figure 2.5.1B, Page 
36). To confirm that InR expression is regulated by the canonical MAPK/ERK 
pathway, I silenced the expression of Raf and D-MEK, which also showed reduced 
InR expression in S2 cells (Figure 2.5.1C, Page 36). In contrast, increasing 
MAPK/ERK pathway activity acts in the opposite direction: depletion of Gap1, the 
GTPase activator of Ras (Gaul et al 1992), led to activation of MAPK/ERK signaling 
visualized by phosphor-specific antibody to the active form of ERK (Figure 2.5.1D, 
Page 36) as well as elevated InR expression (Figure 2.5.1E, Page 36). Thus, 
regulation of InR appears to be a specific MAPK/ERK pathway effect and InR levels 
are sensitive to both positive and negative changes in the MAPK/ERK activity. 
 
How does MAPK signaling affect InR expression? Using quantitative RT-PCR I 
observed a significant reduction in the levels of the mature inr mRNA and the 
unspliced inr primary transcript upon KSR depletion in S2 cells (Figure 2.5.2A, Page 
37). Increasing MAPK activity acts in the opposite direction, as depletion of Gap1 led 
to an increase in inr transcript level in S2 cells (Figure 2.5.2B, Page 37). To examine  
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Figure 2.5.1 MAPK/ERK signaling regulates InR protein expression. 
(A) Immunoblots to visualize the level of InR protein. Cells were treated with dsRNA 
to deplete PI3K, KSR or GFP as a control and after 5 days stimulated with insulin. In 
control cells, insulin stimulation results in a mobility shift in SDS-PAGE. Anti-
Kinesin was used as a loading control. 
(B) Immunoblot to detect the level of InR protein in fat body from wandering 3rd 
instar larvae expressed UAS-RNAi-KSR under Tubulin-GAL4 control. Samples were 
run on the same gel, but intervening lanes have been removed as indicated.  
(C) Immunoblot to visualize the level of InR protein in cells treated with dsRNA to 
deplete Raf or D-MEK. Samples were run on the same gel, but intervening lanes have 
been removed as indicated.  
(D) Immunoblot to visualize the MAPK activity using an antibody specific to the 
phosphorylated form of ERK. S2 cells were treated with two different dsRNAs to 
deplete GAP1 or left untreated. Anti-Kinesin was used as a loading control. Samples 
were run on the same gel, but intervening lanes have been removed as indicated.  
(E) Immunoblot to visualize the level of InR protein in cells treated with dsRNA to 
deplete GAP1. Samples were run on the same gel, but intervening lanes have been 




Figure 2.5.2 MAPK/ERK signaling regulates inr transcription. 
(A) Chart showing the levels of rp49 (Ribosomal protein L32), inr and ksr mRNAs 
measured by quantitative RT-PCR. S2 cells were treated with dsRNA to deplete KSR 
(gray bars) or left untreated (white bars). Total RNA were extracted and normalized 
for cDNA synthesis. RNA levels were normalized to kinesin mRNA. The efficiency 
of ksr depletion was ~60%. “InR” denotes the mature mRNA; “pri-InR” denotes the 
unspliced nuclear primary transcript measured using intron-specific primers. Error 
bars represent standard deviation from 3 independent experiments. Student’s t-test: (*) 
p <0.05. 
(B) Chart showing the levels of rp49 (white bars) and inr mRNAs (gray bars) 
measured by quantitative RT-PCR. S2 cells were treated with two different dsRNAs 
to deplete GAP1 or left untreated. Total RNA were extracted and normalized for 
cDNA synthesis. RNA levels were normalized to kinesin mRNA. 
(C) Chart showing the levels of rp49, inr and ksr mRNAs measured by quantitative 
RT-PCR. Wandering 3rd instar larvae expressed UAS-RNAi-KSR under ubiquitous 
Tubulin-GAL4 control. Controls expressed Tubulin-GAL4 without the UAS-RNAi 
transgene. Total RNA was isolated from imaginal discs, fat body, salivary gland and 
body wall. RNA levels were normalized for cDNA synthesis before Q-PCR. RNA 
levels were normalized to kinesin mRNA. The efficiency of KSR depletion is shown 





the effects of KSR depletion on inr transcript level in vivo, the UAS-KSR RNAi 
transgene was expressed in larvae under Tubulin-GAL4 control. inr transcript levels 
were reduced to differing extents, but significantly in imaginal discs and larval fat 
body (Figure 2.5.2C, Page 37).  
 
Are ~2-fold changes in inr levels as shown in Figure 2.5.2A and C (Page 37) 
sufficient to explain the in vivo phenotypic effects of KSR depletion? To address this, 
I examined the effects of removing one copy of the inr gene on FoxO overexpression 
eyes using two overlapping chromosomal deletion strains to see whether ~2-fold 
changes in inr levels influence the eye phenotype. Df(3R)Exe16186 has a breakpoint 
in the 5’-UTR of inr, and the deletion also uncovers neighboring gene E2F (Figure 
2.6.2C, Page 42). Quantitative RT-PCR confirmed that InR mRNA was reduced to 
~68% of its normal level when Df(3R)Exel6186 was present in one copy (Figure 
2.5.3C, Page 39). Df(3R)Exel6186/+ flies, similar to KSR RNAi flies, had no eye 
phenotype on their own, but significantly enhanced the GMR-FoxO phenotype 
(Figure 2.5.3A and B, Page 39). In contrast, Df(3R)ED6076, which breaks nearby and 
removes E2F but has no impact on inr levels (Figure 2.6.2C, Page 42), had no effect 
on the GMR-FoxO phenotype and had normal eye size on its own (Figure 2.5.3D, 
Page 39). Given that Df(3R)ED6076/+ had no effect, removal of E2F is unlikely to 
contribute to the effects of the deletions reducing inr levels in Df(3R)Exel6186/+ flies. 
Together these experiments show that a reduction of inr levels on the order of 2 folds 
is sufficient to significantly enhance the GMR-FoxO and explain the in vivo effects of 
KSR depletion via reduction of inr levels.  
  
2.6 inr is regulated at the transcriptional level by the ETS-1 orthologue Pointed 
39 
 
Figure 2.5.3 Genetic tests of reduced InR function in vivo. 
(A,B) Adult eyes expressing GMR-GAL4 alone or with UAS-FoxO. Exel/+ indicates 
flies with one copy of the deletion Df(3R)Exel6186 that partially removes inr locus. 
The total area of eyes was measured in pixels from digital images using ImageJ. Error 
bars indicate standard deviation from measurement of at least 5 eyes for each 
genotype. Student’s t-test: (***) p < 0.001. 
(C) Chart showing the level of inr mRNA measured by quantitative RT-PCR in 
control and Df(3R)Exel6186/+ flies. 
(D) Control deletion Df(3R)ED6076 does not sensitize to FoxO overexpression. Adult 
eyes expressing GMR-GAL4 alone or with UAS-FoxO. +/+ indicates 2 intact copies of 
the inr locus. Df(3R)ED6076/+ indicates the flies with one copy of the deletion, 
which is otherwise similar to Df(3R)Exel6186, but does not affect inr. Chart showing 
quantification of eye sizes of the indicated genotypes is shown on the right. Error bars 
indicate standard deviation from measurement of at least 5 eyes for each genotype. 
See Figure 2.6.2C (Page 42) for schematic representation of the deletions used to 





Figure 2.6.1 An InR transgene expressed under heterologous promoter is 
insensitive to KSR depletion. 
(A) Immunoblots to visualize the level of Flag-tagged InR protein expressed under 
control of the pMT promoter in transfected S2 cells. Cells were treated with dsRNA 
to deplete PI3K, KSR or GFP as a control and after 5 days stimulated with insulin. 
Insulin activity was visualized using antibody specific to the phosphorylated form of 
InR (upper panel). Total Flag-InR was visualized with anti-Flag. Anti-Kinesin was 
used as a loading control. Samples were run on the same gel, but intervening lanes 
have been removed as indicated.  
(B) Upper panel: UAS-RNAi-KSR or UAS-FoxO or both were expressed with the 
GMR-GAL4 driver. Lower panel: UAS-InR was driven by GMR-GAL4 with UAS-
RNAi-KSR or UAS-FoxO or both.  
(C) Quantification of the total eye area measured in pixels from digital images using 
Image J. Error bars indicate standard deviation from measurement of at least 5 eyes 
for each genotype. Student’s t-test: (***) p<0.001. (N.S.) indicates that there was no 




The reduction in inr primary transcript levels upon KSR depletion suggests that 
MAPK activity is more likely to act at the level of inr transcription, than via reduced 
stability of the mature transcript. If inr is transcriptionally regulated by MAPK/ERK 
signaling, it can be predicted that ectopic InR expressed from a heterologous promoter 
should override the effects of MAPK inhibition on PI3K/AKT signaling. To test this, 
S2 cells were transfected to express a C-terminal Flag-tagged version of InR and the 
effects of KSR depletion was monitored. In contrast to what was observed using 
antibody to endogenous InR (Figure 2.5.1A, Page 36), the level of transgene 
expressed Flag-InR was insensitive to KSR depletion or to PI3K depletion (Figure 
2.6.1A, Page 40). 
 
As an independent in vivo test of this transcriptional regulation, I used GMR-GAL4 to 
direct expression of a UAS-InR transgene in the eye. Under normal circumstances, 
overexpression of InR causes overgrowth of the eye (Brogiolo et al 2001). This was 
also the case in eyes overexpressing FoxO, compared to GMR-FoxO eyes, indicating 
an increase in insulin-like pathway activity. However, in contrast to the effect of KSR 
depletion on the GMR-FoxO control, KSR depletion did not lead to a reduction in the 
size of eyes expressing UAS-InR under GMR-GAL4 control (Figure 2.6.1B and C, 
Page 40). The apparent insensitivity of transgene-directed InR to the effects of KSR 
depletion is consistent with the hypothesis of a mechanism involving control of 
endogenous inr transcription. 
 
Then what is the transcription factor? By checking those well-established 
transcription factors downstream of ERK (section 3.3, Page 54, and Table 1, Page 55), 
I confirmed the role of Pointed (Pnt), but do not rule out the possibility of other 
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Figure 2.6.2 inr is regulated by the ETS-1 transcription factor Pointed. 
(A) Measurement of inr transcript levels in S2 cells transfected with dsRNA to 
deplete pointed mRNA or left untreated. The efficiency of pointed depletion was 
~70%. “InR” denotes the mature mRNA; “InR-A”, “-B”, “-C”, “-D” denote the four 
splicing isoforms measured using isoform-specific primers. Error bars represent 
standard deviation from 4 independent experiments. Student’s t-test: (*) p <0.05; (**) 
<0.01. 
 (B) Measurement of inr splicing isoform levels in S2 cells transfected with dsRNA to 
deplete ksr mRNA or left untreated. Error bars represent standard deviation from 3 
independent experiments. Samples were the same as used in Figure 2.5.2A (Page 37). 
Student’s t-test: (*) p <0.05. 
(C) Schematic representation of the inr locus. Thick black arrow lines indicate 
transcripts of inr and E2F. The five putative cis-regulatory regions analyzed by 
luciferase assay are shown as black horizontal lines below. The thick line indicates the 
active region, which was used to narrow down to the 0.8 kB element shown in red. 
The Pnt consensus site sequence is indicated in red. Thick gray lines represent 
deletions used in Figure 2.5.3 (Page 39) as well as Figure 2.8.1A-D (Page 48). Note 
that the deletions affect multiple genes. Only inr and adjacent E2F loci are indicated.  
(D) Luciferase assays showing activation of the reporter plasmids after cotransfection 
with a vector to express Pnt-P2 (gray bars) or empty vector as a control (white bars). 
“pro-inr” denotes luciferase reporter with the DNA element from the inr cis control 
region shown in red in (C). “mut” denotes luciferase reporter with the Pnt consensus 
site mutated. pGL3-Basic was used as the control reporter. Error bars represent 
standard deviation based on 4 independent experiments. Student’s t-test: (***) p 
<0.001. 
(E) Immunoblot to visualize the level of InR protein in S2 cells treated with dsRNA to 
deplete Pointed or left untreated. Anti-Kinesin was used as a loading control. 
(F) Immunoblot to visualize the level of AKT S505 phosphorylation in S2 cells 
treated with dsRNA to deplete Pointed. After 5 days cells were stimulated with insulin 






transcriptional mechanisms (Figure 3.1A and B, Page 56). Drosophila pnt encodes an 
ETS-1 transcription factor that is activated by MAPK/ERK through phosphorylation 
of a conserved threonine residue, T151 (Brunner et al 1994; O'Neill et al 1994). I 
tested its involvement in the regulation of insulin-like receptor expression by 
depletion of Pointed from S2 cells by RNAi. This caused a prominent reduction of inr 
mRNA (Figure 2.6.2A, Page 42). To further dissect the effects of KSR and Pointed on 
different inr splicing isoforms, I found that the C-isoform of inr was prominently 
reduced in both cases (Figure 2.6.2A and B, Page 42). Based on this information, I 
systematically analyzed >20 kB upstream of the C-isoform by preparing a series of 
luciferase reporter constructs, which lead to identification of a minimal cis-regulatory 
region of 0.8 kB (Figure 2.6.2C, Page 42). Overexpression of Pointed-P2 in S2 cells 
increased reporter activity directed by this 0.8 kB region (Figure 2.6.2D, Page 42). 
This fragment contained one site perfectly matching the consensus Pointed binding 
site (5’-(C/G)(A/C/G)GGA(A/T)(A/G)-3’). Mutating the consensus site reduced the 
ability of Pointed-mediated regulation of inr gene expression (Figure 2.6.2D, Page 
42). Reciprocally, Pnt depletion in S2 cells led to a decrease in the level of InR 
protein (Figure 2.6.2 E, Page 42), and to a reduction of insulin-induced AKT S505 
phosphorylation (Figure 2.6.2F, Page 42).  
 
To further test this relationship in vivo, I asked whether reducing Pointed levels would 
influence the severity of the FoxO overexpression phenotype of small eyes. Removing 
one copy of the pointed gene using three independent alleles (Alvarez et al 2003; 
Scholz et al 1993) modestly but significantly enhanced the FoxO overexpression 
phenotype in the eye (Figure 2.6.3A and B, Page 44). These findings suggest that 
MAPK/ERK pathway acts via the Ets-1 transcription factor Pointed to control cellular   
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Figure 2.6.3 Independent pointed alleles modestly but significantly enhance the 
FoxO overexpression phenotype in the eyes. 
(A) Upper panel: Photographs of adult eyes. From left to right: GMR-GAL4 alone; 
GMR-GAL4 with one mutant copy of the pointed gene (pnt∆88 allele); GMR-GAL4 + 
UAS-FoxO; GMR-GAL4 + UAS-FoxO with one mutant copy of the pointed gene 
(pnt∆88 allele). Lower panel: Plot of total eye area measured in pixels from digital 
images using Image J. Error bars indicate standard deviation from measurement of at 
least 5 eyes for each genotype. Student’s t-test: (***) p < 0.001. 
(B) Upper panel: adult eyes expressing GMR-GAL4 and UAS-FoxO without or with 
one mutant copy of the pointed gene (pnt07825 or pntT5 allele as indicated). Lower 
panel: plot of total eye area measured in pixels from digital images using Image J. 
Error bars indicate standard deviation from measurement of 7 eyes for each genotype. 






2.7 EGFR is upstream of MAPK/ERK-mediated control in inr expression  
While the in vivo assays using FoxO overexpression in the eye were useful for genetic 
interaction experiments, they did not really address the physiological role of the 
regulatory mechanism identified here under normal condition. A major concern is the 
lack of a physiological demonstration that ERK signaling is indeed naturally used to 
adjust steady-state sensitivity of various tissues to insulin. MAPK/ERK signaling can 
be regulated by a variety of receptor tyrosine kinases (RTKs) (McKay & Morrison 
2007). Therefore, an avenue to resolve this issue would be to identify the upstream 
RTK. I found no evidence for PVR-mediated regulation of inr levels in S2 cells 
(Figure 2.7A) (PVR is the PDGF/VEGF ortholog, and was reported to regulate cell 
size (Sims et al 2009)), neither for InR autoregulaton in vitro (Figure 2.7B, Page 46, 
as InR primary transcripts had no change upon InR RNAi) as well as in vivo, which 
will be discussed later (Figure 2.8.1A, Page 48). To explore whether other RTKs are 
involved in control of MAPK activity upstream of inr expression, I next made use of 
pumpless-GAL4 to manipulate RTK activity. Pumpless is active mainly in the fat 
body, but also other tissues, such as parts of larval gut. Inhibition of Epidermal 
growth factor (EGF) signaling to block MAPK/ERK activity by expression of a 
dominant negative form of EGFR (dnEGFR) (Duchek et al 2001) led to 
downregulation of inr mRNA and protein levels in the isolated fat body (Figure 2.7C 
and D, Page 46). This suggests that EGFR is a physiologically relevant upstream 
regulator of MAPK/ERK-mediated control in inr expression in vivo. The finding is 
further supported by the statistically significant correlation between EGFR target gene 
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Figure 2.7 EGFR-MAPK/ERK signalling regulates inr expression in vivo. 
(A) Chart showing level of rp49, inr and pvr mRNAs measured by quantitative RT-
PCR. Cells were treated with two different dsRNAs to deplete PVR. The efficiency of 
PVR depletions was ~80%.  
(B) Chart showing level of rp49 and inr mRNAs measured by quantitative RT-PCR. 
Cells were treated with dsRNA to deplete mature inr mRNA. “InR” denotes the 
mature mRNA; “pri-InR” denotes the unspliced nuclear primary transcript measured 
using intron-specific primers. Error bars represent standard deviation from 3 
independent experiments. 
(C) Chart showing the levels of rp49 and inr mRNAs measured by quantitative RT-
PCR. Wandering 3rd instar larvae expressed UAS-dnEGFR under pumpless-Gal4 
control. Controls expressed Gal4 without the UAS transgene. Total RNA was isolated 
from the fat body. RNA levels were normalized to kinesin mRNA. Error bars 
represent standard deviation from 3 independent experiments. Student’s t-test: (*) p < 
0.05. 
(D) Immunoblot to visualize the level of InR protein in fat body from wandering 3rd 
instar larvae expressing UAS-dnEGFR under pumpless-Gal4 control. Samples were 
run on the same gel, but intervening lanes have been removed as indicated. 
(E) Correlation between the levels of inr and EGFR target sty mRNAs at various 
stages of Drosophila development. RNA levels were determined using RNA-seq data 
from modENCODE (www.modencode.org) by cufflinks (cufflinks.cbcb.umd.edu). 
Spearman’s correlation coefficient rho=0.71 (P<0.001). E# indicates hours of 
embryonic development. L# indicates larval stage. P# indicates days of pupal 






sprouty and inr gene expression at different stages during Drosophila development 
(Figure 2.7E, Page 46). 
 
2.8 MAPK/ERK regulates inr gene expression to control glucose metabolism 
Systemic regulation of InR activity has been shown to influence metabolic 
homeostasis (Teleman 2010). In this context, the effects of KSR depletion on inr 
transcript as well as FoxO localization in fat body were suggestive of a link to 
metabolism. Since silencing KSR led to ~2-fold changes in inr levels, I made use of 
larvae carrying one copy of the deletion Df(3R)BSC678, which fully removes the inr 
gene, to ask whether reduction of inr to half of normal levels was sufficient to cause a 
metabolic imbalance. Quantitative RT-PCR was used to confirm that inr mRNA 
levels were reduced to ~50% in this condition (Figure 2.8.1A, Page 48) (note that this 
indicated little or no feedback from InR signaling on inr expression, suggesting 
limited output from InR via the MAPK pathway; otherwise, stronger effect could be 
expected if InR regulated MAPK).  
 
Larvae lacking one copy of the inr gene showed no significant change in levels of 
stored glycogen and triglycerides or trehalose (Figure 2.8.1B and C, Page 48), a 
circulating disaccharide in insects synthesized by the fat body through glycogenolysis 
(Becker et al 1996) and broken down into glucose by the catabolic enzyme trehalase 
for usage (Isabel et al 2005). However, levels of circulating glucose in the hemolymph 
were substantially increased (Figure 2.8.1D, Page 48), suggesting compromised 
clearance of dietary glucose from the circulation. To ask whether this glucose defect 
could be achieved by independent genetic means, I used pumpless-GAL4 to drive  
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Figure 2.8.1 InR expression is critical for maintaining levels of circulating 
glucose. 
(A) Chart showing the levels of rp49 and inr mRNAs measured by quantitative RT-
PCR in control (+/+) and Df(3R)BSC678/+ larvae. “InR” denotes the mature mRNA; 
“pri-InR” denotes the unspliced nuclear primary transcript. Error bars represent 
standard deviation from 3 independent experiments.  
(B) Charts showing glycogen (left) and triglyceride (right) levels normalized to total 
protein in control (+/+) and Df(3R)BSC678/+ larvae. Error bars represent standard 
deviation from 3 independent experiments. 
(C) Chart showing trehalose levels in hemolymph from wandering 3rd instar control 
(+/+) and Df(3R)BSC678/+ larvae. 
(D) Chart showing glucose levels in control (+/+) and Df(3R)BSC678/+ larval 
hemolymph. Error bars represent standard deviation from 3 independent experiments. 
Student’s t-test: (**) p <0.01. 
(E) Chart showing glucose levels in hemolymph from larvae expressing UAS-InRRNAi 
under pumpless-Gal4 control. Error bars represent standard deviation from 3 
independent experiments. Student’s t-test: (*) p <0.05. 
(F) Chart showing glucose levels in hemolymph from wandering 3rd instar larvae 
expressed UAS-InR under Tubulin-GAL4 control. Error bars represent standard 




expression of a UAS-RNAi-InR transgene to deplete InR in the fat body to generate a 
similar phenotype, and these animals indeed also showed elevated glucose in their 
hemolymph (Figure 2.8.1E, Page 48), verifying that regulation of InR levels is 
physiologically important in vivo in maintaining levels of circulating glucose. This 
conclusion was further supported by the finding that ubiquitous InR overexpression 
modestly, but significantly, decreased levels of circulating glucose (Figure 2.8.1F, 
Page 48). These findings are consistent with what was observed in flies with 
compromised production of ILPs resulting from genetic ablation of the insulin-
producing neurosecretory cells (Broughton et al 2005) mentioned in section 1.1.5 
(Page 14). Those flies showed a prominent metabolic change in circulating glucose 
levels as well. Similarly, insulin signaling in mammals is responsible for triggering 
glucose uptake and release, and reduced insulin sensitivity is linked to hyperglycemia, 
metabolic syndrome and type-2 diabetes (Eckel et al 2005; Welsh et al 2005).  
 
To test whether MAPK/ERK-regulation of InR expression was involved in 
maintaining systemic glucose homeostasis, I assessed the effects of KSR RNAi. 
Ubiquitous depletion of KSR led to elevated levels of circulating glucose (Figure 
2.8.2A, Page 50), but almost normal levels of circulating trehalose (Figure 2.8.2B, 
Page 50). If the effect of KSR depletion is due to reduced inr levels, I would expect 
restoring inr expression under Tubulin-GAL4 control to lower glucose levels toward 
normal. This proved to be the case (Figure 2.8.2A, Page 50). As expected, expression 
of the dnEGFR using the pumpless-GAL4 driver also resulted in elevated circulating 
glucose (Figure 2.8.2C, Page 50). The glucose levels were restored by simultaneous 
overexpression of Pointed (Figure 2.8.2D, Page 50), which is in agreement with the 
view that Pointed acts as a downstream effector of InR expression. These observations 
50 
 
Figure 2.8.2 MAPK/ERK regulates inr expression to control glucose levels.  
(A) Chart showing the levels of circulating glucose in hemolymph. Wandering 3rd 
instar larvae expressed UAS-KSRRNAi under Tubulin-GAL4 with or without co-
expressed UAS-InR. Controls expressed Gal4 without the RNAi transgenes. Student’s 
t-test: (**) p < 0.01. 
(B) Chart showing trehalose levels in hemolymph from wandering 3rd instar larvae 
expressing Tubulin-GAL4 or with KSR RNAi transgenes.  
(C) Chart showing glucose levels in hemolymph from larvae expressing UAS-
dnEGFR under pumpless-GAL4 control. Error bars represent standard deviation from 
3 independent experiments. Student’s t-test: (*) p <0.05. 
(D) Chart showing the levels of circulating glucose from larvae expressing UAS-
dnEGFR without or with overexpression of Pointed-P2 under pumpless-GAL4 control. 
Error bars represent standard deviation from 3 independent experiments. Student’s t-






suggest a physiological role for EGFR-MAPK/ERK-Pointed activity in control of 




























3.1 Growth and metabolism through crosstalk during development 
Ras, Raf and other MAPK pathway components are well known as oncogenes 
because of their roles in control of cell proliferation and cell survival in mammalian 
system. Previous studies have implicated activated Ras, an upstream activator of the 
MAPK pathway in control of cellular and tissue growth rates during Drosophila 
development (Karim & Rubin 1998; Prober & Edgar 2000; 2002). As well, Raf, but 
not the canonical downstream ERK pathway has been shown to control cell 
proliferation and survival by regulating the Ste-20 kinase Slik (Hipfner & Cohen 
2003). In cell based assays, activation of the MAPK pathway by the EGF and 
PDGF/VEGF growth factor receptors controls cell size in Drosophila (Sims et al 
2009). 
 
In vivo, RNAi-mediated depletion of KSR or Raf causes reduction of tissue area and 
of cell size in a manner that resembles the effects of reducing insulin-like pathway 
activity by depletion of AKT (Figure 2.1.1, Page 24). The work reported here 
provides evidence for a second mechanism through which growth factor receptor 
signaling via the MAPK/ERK pathway modulates insulin-like pathway activity 
(section 1.3, Page 21). Transcriptional control of inr gene expression by EGFR 
signaling may provide a means to link developmental signaling to regulation of 
metabolism. Indeed, a statistically significant correlation is noted between EGFR 
target gene sprouty and inr gene expression at different stages during Drosophila 




The MAPK and PI3K/AKT pathways are both activated by growth factor signaling to 
promote tissue growth. During development, tissues are in a phase of rapid growth. 
Cellular growth rates are limited by nutritional signals, such as energy (glucose) and 
amino acids, which act at the single cell level and are mediated by regulation of 
TORC1 (Hietakangas & Cohen 2009). Tissues also monitor systemic level nutritional 
inputs through insulin, which acts through AKT on TORC1 and FoxO. In Drosophila, 
the growth phase takes place during larval stages. The role of insulin-like signaling in 
the adult is primarily metabolic, since there is limited cellular growth and division 
after larval stages. It is possible that fast cellular growth during larval stages is 
enhanced by the use of the MAPK pathway to change cellular insulin responsiveness, 
via using the same set of ligands and receptors in both growth and metabolism.  
 
3.2 Short term vs long term mechanisms to modulate insulin responsiveness 
Several steps of the insulin-like pathway can be regulated by phosphorylation. Given 
that the MAPK/ERK pathway is a kinase cascade, a priori, the possibility of 
phosphorylation-based interaction between these pathways would seem likely. 
However, this appears not to be the case. Acute pharmacological inhibition of the 
MAPK/ERK pathway proved to have no impact on insulin-like pathway activity 
(Figure 2.3D, Page 31). Thus short-term changes in MAPK/ERK pathway activity do 
not seem to be used for transient modulation of insulin-like pathway activity. Instead, 
the MAPK/ERK pathway acts through the Ets-1 type transcription factor Pointed to 
control expression of the inr gene. Transcriptional control of inr suggests a slower, 
less labile influence of the MAPK pathway. Taken together with the earlier studies 
(Prober & Edgar 2002), the findings presented here suggest that growth factor 
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signaling can regulate insulin sensitivity by both transient and long-lasing 
mechanisms.  
 
Why use both short-term and long-term mechanisms to modulate insulin 
responsiveness to growth factor signaling? The use of direct and indirect mechanisms 
that elicit a similar outcome is reminiscent of feed-forward network motifs (Alon 
2007). Although these motifs are often thought of in the context of transcriptional 
networks, the properties that they confer are also relevant in the context of more 
complex systems involving signal transduction pathways. In multicellular organisms, 
feed-forward motifs are often used to make cell fate decisions robust to environmental 
noise (Herranz & Cohen 2010; Li et al 2009). The findings from this work suggest a 
scenario in which a feed-forward motif is used in the context of metabolic control, 
linking growth factor signaling to insulin responsiveness. In this scenario, growth 
factor signaling acts directly via Ras to control PI3K activity and indirectly via 
transcription of the inr gene to elicit a common outcome – sensitization of the cell to 
insulin. This arrangement allows for a rapid onset of enhanced insulin sensitization, 
followed by a more stable long-lasting change in responsiveness. Thus a transient 
signal can both allow for an immediate as well as a sustained response. The 
transcriptional response also makes the system stable to transient decreases in steady-
state growth factor activity. I speculate that this combination of sensitivity and 
stability allows responsiveness while mitigating the effects of noise resulting from the 
intrinsically labile nature of RTK signaling.  
 
3.3 Screen of transcription factors downstream of ERK regulating inr 
55 
 
Table 1 Transcription factors downstream of ERK for RNAi screen in S2 cells. 
Gene Name Symbol CG Number Mammalian 
Homology 
anterior open aop/yan CG3166 TEL 
Sin3A Sin3A CG8815 Sin3A 
lilliputian lilli CG8817 lilliputian 
brother of odd with entrails limited bowl CG10021 bowl 
diminutive Dm/Myc CG10798 c-Myc 
NFAT homolog NFAT CG11172 NFAT 
split ends spen CG18497 Split ends 
pointed pnt CG17077 Ets-1 





Figure 3.1 Transcription factors NFAT and Yan are downstream of ERK. 
(A) Immunoblots to visualize the level of InR protein in S2 cells treated with dsRNA 
to deplete NFAT or PI3K or left untreated. Note that there was no obvious feedback 
on InR protein level in PI3K depleted cells (Lane 3). Anti-Kinesin was used as a 
loading control. Samples were run on the same gel, but intervening lanes have been 
removed as indicated. 
(B) Immunoblots to visualize the level of AKT S505 phosphorylation in S2 cells 
treated with dsRNA to deplete NFAT or PI3K or left untreated. After 5 days cells 
were stimulated with insulin (30 min). Samples were run on the same gel, but 
intervening lanes have been removed as indicated. 
 (C) Immunoblot to visualize the level of InR protein in S2 cells treated with dsRNA 
to deplete Yan or left untreated. Samples were run on the same gel, but intervening 






In order to build the MAPK/ERK-Pnt-InR axis, in total ten well-established 
transcription factors downstream of ERK (Table 1, Page 55) were checked in S2 cells 
by RNAi-mediated gene silencing. Besides Pnt, there was another transcription NFAT 
(CG11172)  (Huang  &  Rubin 2000) ,  when  depleted ,  also  showing  reduced  InR 
expression as well as reduced insulin-induced AKT phosphorylation (Figure 3.1A and 
B, Page 56). However, I was not able to exclude the possibility that this is due to 
certain non-specific effect since the NFAT depletion cells were extremely sick. 
Therefore, it remains an open question whether the transcription factor NFAT is 
involved or not. 
 
Moreover, the transcription repressor Yan (CG3166) was in the list as well. Yan has 
been shown to be regulated by the MAPK/ERK signaling and functions as an 
antagonist of Pnt in many but not all situations (Brunner et al 1994; O'Neill et al 
1994).  Both Pnt and Yan belong to the same Ets family of transcription factors, 
recognizing the same core motif 5′ -(C/G)(A/C/G)GGA(A/T)(A/G)-3′. As a result, 
Yan competes with Pnt, acting as a repressor binding to the same DNA region 
through its Ets domain. Despite of this competition, I did not observe significant 
change in InR expression upon Yan knockdown (Figure 3.1C, Page 56). This 
indicates that the Ets protein binding site inside the inr promoter is specific for Pnt 
rather than for both Pnt and Yan. Further bioinformatic studies are needed to analyze 
the flanking sequences next to the Ets core motif that are believed to help determine 
which Ets protein will bind (Wasylyk et al 1993).  
 
3.4 The role of two Pnt splicing isoforms 
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The transcription factor Pnt expresses P1 and P2 two isoforms, having the same Ets 
domain that determines the DNA binding specificity and allows them to share 
common transcription targets. However, there is only solid evidence showing that 
MAPK / ERK  regulates  PntP2  activity  by  direct  phosphorylation  of  a  single 
phosporylation site T151, which is missing in PntP1 due to alternative splicing. Then, 
is P1 isoform also regulated by MAPK? One appealing model, although has not been 
proven, is that activated PntP2 might act to turn on the PntP1 promoter (O'Neill et al 
1994). In that scenario, PntP1 is transcriptionally responsive to the MAPK activity. 
This makes a transient signal through MAPK to PntP2 be maintained by PntP1 
because P1, different from P2, is known to be a constitutive activator of transcription. 
 
If so, what are the roles of the two isoforms in the MAPK/ERK-Pnt-InR axis here? 
My preliminary data from S2 cells revealed that knockdown PntP2 brought down inr 
transcript level and meanwhile elevated pntp1 mRNA, whereas depleting PntP1 did 
not make any difference on other genes expression (Figure 3.2, Page 59). Although 
some part of the data seems against the proposed model above, there is no doubt that 
it is PntP2 rather than PntP1 controlling inr expression. This PntP2 dependent 
regulation, however, still needs to be verified by further experiments.  
 
3.5 Transcriptional regulation of inr expression by FoxO and by Pointed 
Earlier studies by Puig and coworkers have shown that the transcription of the inr 
gene is under dynamic control (Puig et al 2003; Puig & Tjian 2005). Activation of 
FoxO in the context of low insulin-like signaling leads to up-regulation of inr 
transcription, thus constituting a negative feedback regulatory loop. Together with this 
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Figure 3.2 PntP2 rather than PntP1 regulates inr expression in S2 cells. 
Chart showing the levels of rp49, inr, pntp1 and pntp2 transcripts measured by 
quantitative RT-PCR. S2 cells were treated with isoform-specific dsRNA to deplete 
PntP1 (white bars) or PntP2 (gray bars). RNA levels were normalized to Kinesin 




study, InR expression is under control of two receptor-activated cues, which appear to 
be competing in nature. On one hand inr expression is positively regulated by the 
EGFR-MAPK/ERK-Pnt module, but negatively regulated by its own expression via 
FoxO. However, the cis-regulatory elements in the inr promoter recognized by the 
two cues, or the two transcription factors, Pnt and FoxO, turned out to be different 
based on this work and (Puig et al 2003), which indicates that the two effects are 
likely not competing with each other at the DNA level. Thus, it seems that the 
outcome of the two opposite regulatory effects depends on which effect is stronger 
under the physiological conditions of the tissues being examined. Switch or 
coordination between these two types of regulation will be potentially interesting. 
Some indication from (Puig et al 2003) is that, under starvation, negative feedback via 
FoxO appeared stronger, as fasted flies had more inr transcripts. 
 
In the setting of this study, however, the cross-regulatory MAPK/ERK pathway 
seemed to dominate over the negative autoregulatory mechanism, as shown in Figure 
2.7B (Page 46), Figure 2.8.1A (Page 48, as both mature and primary InR mRNA 
reduced to a similar level) and Figure 3.1A (Page 56, as decreasing insulin pathway 
activity by PI3K depletion did not increase InR protein level). This is perhaps not 
surprising, since the opposite scenario would dampen any cross regulatory effects. 
There are conditions, or cell types, in which this balance differs. For example, 
previously cell-based RNAi screens have been performed to assess the effects of 
depleting phosphatases and kinases on FoxO activity (Mattila et al 2008). Compared 
with the in vivo screen done by Ville, both screens identified some known upstream 
regulators of AKT, such as PI3K and PDK1. The cell-based screen reported novel 
roles for protein kinase C and glycogen synthase kinase 3β in regulating FoxO 
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activity. These were not found among Ville’s collection of in vivo modifiers. 
However, the cell-based assays did not identify MAPK pathway components. These 
differences are likely because in their cells the auto-regulatory mechanism is 
dominant to prevent the influence from any cross talk. To support this, I noticed that 
the S2 cells used in my experiments have low or no endogenous FoxO expression, 
whereas this is not the case for the cell-based RNAi screens as shown by their 
immunoblots (Mattila et al 2008). Therefore, the absence of endogenous FoxO breaks 
down the auto-regulatory feedback loop and permits the cross-regulatory from MAPK 
signal to take place.  
 
3.6 Metabolism of circulating sugars, stored glycogen and triglyceride 
The EGFR-MAPK/ERK-Pointed mediated control of inr permits physiological 
adjustment of insulin sensitivity and subsequent maintenance of circulating glucose at 
appropriate levels. As illustrated by my data, failure of this regulation in the fat body 
leads to elevated circulating glucose levels, likely reflecting impaired clearance of 
dietary glucose from the circulation by the fat body. Maintaining circulating free 
glucose levels low is likely to be important due to the toxic effects of glucose (Becker 
et al 1996). Similarly, disturbance in insulin sensitivity in humans leads to impaired 
clearance of glucose from the bloodstream, which is a hallmark of diabetes. 
 
In contrast, circulating trehalose, glycogen or triglyceride levels showed no significant 
change in larvae with reduced InR expression. Previous studies at adult stage have 
already shown various metabolic defects in sugar and lipid store by manipulating the 
core components of the insulin-like pathway (Bohni et al 1999; Hennig et al 2006; 
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Luong et al 2006; Oldham et al 2002; Scott et al 2004; Shingleton et al 2005; 
Varghese et al 2010). The difference between this work and previous studies probably 
reflects that these aspects of energy metabolism (trehalose, glycogen and triglyceride) 
at larval stage can be maintained through compensatory mechanisms in conditions of 
moderately impaired insulin-like signaling, as the role of this pathway in metabolism 
is primarily in the adults.  
 
3.7 Evolutionary conservation of MAPK/ERK-Pnt-InR axis  
Both insulin-like signaling pathway and MAPK/ERK signaling are evolutionarily 
conserved, thus it is easy to ask whether the cross-regulatory mechanism described 
here also occurs in mammalian cells. To address this issue, KSR1 was knocked down 
by Ville in MCF7 and PC3 tumor cells via siRNA. However, he did not observe any 
response from insulin receptor expression by quantitative RT-PCR. Unlike 
Drosophila, human has two KSRs, KSR1 and KSR2, which might function 
redundantly for MAPK/ERK signal transduction (Claperon & Therrien 2007). This 
could protect the system from collapse upon KSR1 depletion. On the other hand, in 
human, distinct forms of the ligands and their receptors, insulin vs IGF, are used in 
metabolic and growth regulatory contexts. Hence, it is possible that the crosstalk in 
human does happen, but it happens to IGF receptor instead of insulin receptor.  
 
However, it is more likely that this regulatory mechanism is insect specific. Though 
all the signaling components studied here are highly conserved, they may not be 
expected to share the same molecular properties and function in insect and mammal. 
As discussed in 3.1 (Page 53), the growth and metabolic regulatory functions of the 
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insulin-like signaling pathway are partially although not completely segregated in 
Drosophila in different developmental phases: growth primarily in larval stages 
whereas metabolism in adult stages. This scenario differs from mammalian systems 
where the two functions occur concurrently but distinguished by different forms of 
ligands and their receptors (Nakae et al 2001a; Yamaguchi et al 1995). Therefore, it 
looks as though that insects need crosstalk between nutritional signals to better 
coordinate growth with metabolism during development. Hence, different solutions 
perhaps have been found in mammals and insects to allow the conserved insulin/IGF 
pathway to be used differently in different contexts.  
 
Finally, it is also possible that the strong InR-INRS feedback loop via FoxO1 “kills” a 
feed forward motif in mammals. To maintain its stability in the face of a more 
complicated environment, the mammalian system enhances its insulin signaling 
negative feedback by additional control of INRS through FoxO1 (Puig & Tjian 2005). 
Hence, to some extent, the self regulatory loop of the pathway appears stronger in 














Disturbance in insulin signalling is common in human metabolic disorders. Insulin 
resistance occurs when insulin becomes less effective to lower blood sugars, resulting 
in increased blood glucose concentration and consequently type-2 diabetes. Quite 
often there is an association of high insulin levels, central obesity, elevated cholesterol, 
and/or hypertension, which is termed metabolic syndrome.  
 
Drosophila serves as a perfect model to study the insulin signalling in humans, 
because many key components of the pathway only have a single gene in this simple 
organism. The purpose of this thesis is to better understand the modulations that 
adjust the sensitivity of the insulin responsiveness to extracellular stimuli. 
Discovering these more subtle relationships poses a challenge that can be approached 
by genetics screens in Drosophila performed using sensitized genetic backgrounds. 
To this point, this work successfully illustrated the molecular mechanism and 
physiological function of such a modulatory regulation.  
 
However, it is still too early to say whether this work contributes to our knowledge 
regarding metabolic syndromes in humans, since this subtle modulation from 
MAPK/ERK may not occur out of the insect kingdom. More detailed exploration in 
mammals is required to fully evaluate the significance of this study. Nevertheless, the 
analysis here has set up an example to investigate novel regulations of the insulin-like 
pathway, based on which my other project (not presented here) has found a new 
regulator of insulin signalling in both Drosophila and human that can be a druggable 
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target and might provide a promising strategy for relieving insulin resistance in 
diabetic patients.    
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5 Materials and Methods 
 
5.1 Fly strains 
The following fly strains are from Cohen lab’s fly stock collection: GMR-GAL4, 
UAS-p35 (II), UAS-Dp110 CAAX, pumpless-GAL4. 
 
sty∆5 (BL6382), UAS-InR (BL8262), pnt∆88 (BL861), pnt07825 (BL11724), UAS-Pnt-P2 
(BL399), ksrS-627 (BL5683), Df(3R)Exel6186 (BL7665), Df(3R)ED6076 (BL8962) 
and Df(3R)BSC678 (BL26530) flies were obtained from the Bloomington Stock 
Center. UAS-RNAi-PI3K (GD transformant ID 38985), UAS-RNAi-KSR (GD) and 
UAS-RNAi-InR (GD transformant ID 992) lines were from the Vienna Drosophila 
RNAi center. 
 
 pUAST-FOXO-GFP flies were provided by Aurelio Teleman. Tubulin-GAL4 (II) 
were provided by Cai Yu. pUAST-dnEGFR flies were provided by Pernille Rørth. 
pntT5 flies were provided by Christian Klämbt.  
 
5.2 Plasmids 
The following plasmids are from Cohen lab’s plasmid collection: pMT-GAL4, 
pUAST-FoxO-GFP (Teleman et al 2005b), pUAST-Myc-Dp110 CAAX (Leevers et al 





inr transcripts without UTR sequences were amplified from S2 cell cDNA library 
with primers having a Flag tag at C-terminal. The following primers were used to 
amplify InR-Flag and clone it into pMT/V5-His vector with EcoRI, NotI and XhoI 








The primers used to clone pntp2 into pMT-Myc-puromycin (Easow et al 2007) by 






5.2.3 A series of inr promoter luciferase reporter constructs 
All luciferase reporter constructs used SLIC at XhoI site on pGL3-Basic. Primers 
used for different fragments are listed as following: 




3’; reverse 1, 5’-AAGCTTACTTAGATCGCAGATCTGATTAGACCGAGGTAAA 
C-3’; and forward 2, 5’-GCGTGCTAGCCCGGGCTCGAGTGGGCAAACGATGTT 
ATTGC-3’; reverse 2, 5’-AAGCTTACTTAGATCGCAGATTTAGCACAAAAGCA 
TTCCAC-3’; and forward 3, 5’-GCGTGCTAGCCCGGGCTCGAGAACAATGTGG 
AGCTTAAGAG-3’; reverse 3, 5’-AAGCTTACTTAGATCGCAGATAGCAACAG 
ACTGCAACAGTG-3’; and forward 4, 5’-GCGTGCTAGCCCGGGCTCGAGATTC 
GCACTGTTGCAGTCTG-3’; reverse 4, 5’-AAGCTTACTTAGATCGCAGATTGA 
GGCAAAATCAGAATAGC-3’ (this DNA region is indicated by the thick black 
horizontal line in Figure 2.6.2C (Page 42), and the activities of reporter construct 
having it are shown in Figure 5 (Page 69) responding to the levels of Pnt); and 
forward 5, 5’-GCGTGCTAGCCCGGGCTCGAGCGAGACTCGCAGAAATATAG-
3’; reverse 5, 5’-AAGCTTACTTAGATCGCAGATGGAGAACTACATAAGCAAA 
G-3.  
Primers for further narrowing down the region shown as thick black horizontal line in 
Figure 2.6.2C (Page 42): 
Forward 4-1, 5’-GCGTGCTAGCCCGGGCTCGAGGGGAACAAGATTGACATAC 
A-3’; and forward 4-2, 5’-GCGTGCTAGCCCGGGCTCGAGCGGAGCTTGCTGT 
GCAATTA-3’; reverse 4-2, 5’-AAGCTTACTTAGATCGCAGATTTCCCTACCGT 
TAGTTGAAG-3’; and forward 4-3, 5’-GCGTGCTAGCCCGGGCTCGAGTGAGA 
GTTTCATGTGTCAGA-3’; reverse 4-3, 5’-AAGCTTACTTAGATCGCAGATGTT 
AATTGCACAGCAAGCTC-3’ (primers 4-3 were used to clone the 0.8 kB element 
shown in red in Figure 2.6.2C (Page 42) into pGL3-Basic at HindIII and XhoI sites); 




Figure 5 Luciferase reporter responded to Pnt levels in S2 cells. 
(A) Luciferase assays. “pro-inr #4” denotes luciferase reporter with the DNA region 
indicated by the thick black horizontal line in Figure 2.6.2C (Page 42). pGL3-Basic 
was used as the control reporter. Cells were treated with dsRNA to deplete Pnt (gray 
bars) or GFP (white bars) for 4 days. Error bars represent standard deviation based on 
3 independent experiments. (**) Student’s t-test < 0.01. 
(B) Luciferase assays showing activation of the reporter plasmids (as in panel A) after 
cotransfection with a vector to express PntP2 (gray bars) or empty vector as a control 





5.2.4 Mutagenesis of Pnt consensus site 
The primers used to mutate the predicted Pnt consensus site in the region amplified by 
primers 4-3 (section 5.2.3, Page 68) were:  
forward, 5’-GAGAATGCCGGAGATGAAGACGCGAACGAAGATGAAGTCGAT 
G-3’; reverse, 5’-CATCGACTTCATCTTCGTTCGCGTCTTCATCTCCGGCATTC 
TC-3’.  
Reaction was conducted using QuickChange II XL kit. 20 cycles were used for PCR 
amplification. 
 
5.3 Cell culture and treatments 
S2 cells were grown at 25 degree in SFM (Gibco) supplemented with L-glutamine. 
Cells were treated with 37nM dsRNA for 4 days, or 5 days with two boosts on day 1 
and day 3. Cells were transfected with different plasmids using effectene reagent 
(QIAGEN): DNA was mixed with EC buffer before incubated with Enhancer at room 
temperature for 2-3 min. Then, Effectene was added and vortexed immediately before 
10 min incubation at room temperature. Cells were dispensed after DNA mixture was 
seeded on the plates. For plasmids having metallothionein promoter, 0.7 mM CuSO4 
was used to induce protein expressions after transfection.  
 
5.4 In vitro dsRNA transcription for S2 cell RNAi 
Material: 




CDS or transcripts of interesting genes were blasted in Flybase and 400-600 base pair 
DNA regions with less homologous to other genes were selected for designing PCR 
primers both with T7 promoter sites. 2 ul cDNA library from S2 cells was used as 
template in 100 ul PCR reaction solution with Phusion high-fidelity DNA polymerase 
(Finnzymes). PCR products were purified using QIAGEN kit and dissolved in 30 ul 
water, from which 8 ul was used and mixed with other components from Megascript 
kit to make a 20 ul reaction mixture, incubated at 37 degree overnight. On the second 
day, 1 ul DNase from the kit was added into each reaction and incubated at 37 degree 
for another 15 min. After that, the reaction was shifted to 65 degree for 30 minutes to 
get ssRNA, then slowly cooled down to room temperature for ~ 1 hr to allow ssRNA 
to form dsRNA. After added 30 ul water and 30 ul lithium chloride, and chilled at -20 
degree for more than 30 min, dsRNA was recovered by centrifuging at 14000 rpm for 
15 min at 4 degree. The pellet was washed with 1 ml 70% ethanol before dissolved in 
water. Concentration of the dsRNA was measured in Nanodrop. Quality of the 
dsRNA annealing was checked on DNA agarose gel before use or storage at -20 
degree.   
 
Primers used for in vitro synthesis of dsRNA against different genes are listed in 
Table 2 (Page 72-73). If targeted gene has multiple splicing isoforms, common region 
was selected for primer design, except the case where individual isoform was needed 














5.5 Cell imaging 
For FoxO-GFP localization, live S2 cells were imaged using a Leica SP5 confocal 
microscope. Images were taken of random fields within 15 min after 10 ug/ml insulin 
boost for 30 min and scored for GFP localization (scoring was done ‘blind’). For 
GFP-PH images were taken within 10 min after 10 ug/ml insulin boost for 5 min. The 
ratio of membrane to cytoplasmic GFP levels was measured as pixel intensity along 
the white line as indicated in Figure 2.4A (upper panel, Page 33). 
 
5.6 Fat body FoxO immunofluorescent staining 
Materials: 
PBT Buffer: 
0.05% Triton X-100 in PBS 
Mounting Medium: 
80% glycerol and 0.4% propylgalate in PBS 
Methods: 
Newly hatched 1st instar larvae were seeded at 50/vial and reared at 25 degree. 
Wandering 3rd instar larvae were dissected. Tissues were fixed in PBS with 4% 
paraformaldehyde for 20 min and blocked in PBT with 5% BSA for 1hr at room 
temperature. Anti-FOXO antibody was used at 1:1000 dilution overnight at 4 degree. 
Before 2nd antibody and DAPI labeling, tissues were washed in PBT with 1% BSA. 
Fat body connected with salivary gland was imaged in mounting medium using a 






5X SDS sample buffer  
7ml 1M Tris pH6.8, 6ml glycerol, 2.56g SDS, 1.86g DTT, 0.01g Bromphenol blue 
and water to make 20ml. 2.5X buffer was obtained by diluting 5X buffer with PBS. 
10X SDS PAGE running buffer 
30.2g Tris-Base, 188g glycine, 100ml 10% SDS solution and water to make 1L. 
Bio-Rad Precision Plus Protein Standards (Dual Color) 
Transfer buffer  
1 volume methanol with 4 volume 1X SDS PAGE running buffer. 
Whatman Protein BA85 Nitrocellulose Transfer Membrane 
Owl Semi-Dry Electroblotter 
Ponceau S solution for electrophoresis (SERVA 33427.01) 
TBS washing buffer  
10mM Tris pH7.4, 150mM NaCl and 0.1% Tween 20 in water. 
Non-fat dried milk powder 
Western Lighting Plus-ECL 
Amersham Hyperfilm (GE Healthcare) 
Methods: 
S2 cells or fly tissues were homogenized in 2.5X SDS sample buffer, boiled at 100 
degree for 5-10min and resolved by SDS-PAGE gel before transferring (200mA per 
gel) to nitrocellulose membranes for antibody labeling. Primary antibodies were 
incubated in TBS with 1% BSA at 4 degree over night after blocking in 3% milk at 
room temperature for at least half an hour.  After 2hr incubation with 2nd antibodies, 
membranes were developed in ECL reagents at room temperature for 1min. 
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Antibodies to phosphor-S505-AKT (1:2000), AKT (1:1000), P-InR (1:1000) and Myc 
(1:1000) were from Cell Signaling Technology. Anti-Kinesin (1:10000) was from 
Cytoskeleton. Phospho-ERK antibody (dp-ERK, 1:1000) was from Sigma. Anti-S6K 
(1:30000) is described in (Stewart et al 1996). Anti-dInR (re-cycled, 1:1000) is 
described in (Puig & Tjian 2005). 
 
5.8 RNA extraction and quantitative RT-PCR 
Materials: 
Trizol (Invitrogen)  
RNeasy Mini Kit (QIAGEN) 
Superscript III first strand synthesis (Invitrogen) 
POWER SYBR GREEN Master Mix (Applied Biosystems) 
Methods: 
Wandering third instar larvae were dissected in chilled PBS. Different tissues were 
collected and kept in 10 ul serum free S2 cell media (SFM Gibco) supplemented with 
L-glutamine on ice. After dissection samples were shifted to – 80 degree for storage. 
For immediate RNA extraction, 800 ul or 1 ml Trizol reagent (depends on sample 
amount) was added to samples and homogenized using 1 ml syringe. After that, cell 
lysate was transferred to appropriate sized Phase Lock Gel-Heavy tubes and incubated 
for 5 min at room temperature. 400 ul chloroform per 1 ml Trizol reagent was added 
into each tube and shaked vigorously for 15 seconds (do not vortex) before 
clarification by centrifugation at no more than 12 Kg for 10 min at 4 degree. The 
upper aqueous phase was well mixed with 1 volume of 70% ethanol and transferred 
into RNeasy spin column from RNeasy Mini Kit. From this step on, on-column 
77 
 
DNase digestion to eliminate genomic DNA contamination, as well as RNA 
purification was carried out following the handbook in RNeasy Mini Kit.  
 
For total RNA extracted from S2 cells in 24 well plate, 350 ul RLT buffer (RNeasy 
Mini Kit) with 1% 2-ME was added into each well and homogenized with 1 ml 
syringe up and down after removing the media. On-column DNase treatment and 
RNA purification were performed following the handbook in RNeasy Mini Kit as 
well.  
 
Finally, total RNA was dissolved in 30 ul water and RNA concentration was 
measured in Nanodrop for normalization. Same amount of total RNA (around 1 ug 
RNA) was used for all parallel samples in 8 ul water out of 20 ul reaction solution. 
Reverse transcription to synthesize the first strand used oligo-dT primers and 
Superscript RT-III (Invitrogen). The reaction was performed in PCR cycler following 
the protocol from Supperscript III kit. 
 
After that, 20 ul cDNA was diluted in 180 or 200 ul water as DNA template for real-
time PCR. 12.5 ul POWER SYBR GREEN Master Mix (Applied Biosystems), 1 ul 
diluted PCR primer mixture and 6 ul DNA template were used to make a 25 ul PCR 
solution with water. Real-time PCR was performed in 96 well-plate and analyzed on 
Applied Biosystems 7500 fast real-time PCR system.  
 
Primers used for real time PCR are listed in Table 3 (Page 78). 100uM primer stocks 
were diluted 1:1:16 in water to make a 6.25 uM primer mixture and used for real-time 







have to avoid the region targeted by dsRNA. 
 
5.9 Glucose and trehalose assay from hemolymph of Drosophila larvae 
Material:  
GAGO-20 kit (Sigma): 
First, glucose oxidase reagent [G3660] was dissolved in an amber bottle with 39.2 ml 
of deionized water, then mixed well and stored in exact 5 ml aliquots. It is stable for 6 
months at -20 degree. Second, o-Dianistidine [D2679] was reconstituted with 1 ml of 
deionized water, and avoided to expose to light. It is stable for 3 months at 2-8 degree. 
Finally, 102 ul of o-Dianisidinereagent was mixed with 5 ml glucose oxidase reagent 
to make assay reagent. 
Methods: 
Controlled growth conditions were used for all experiments related to metabolism. 1st 
or 2nd instar larvae were collected. GFP or Tm6 Tb balancers were used to allow 
genotyping. Same number larvae (50 or 60) were seeded in fresh vials and reared at 
25 degree. Hemolymph was extracted from clean and dry wandering stage 3rd instar 
larvae. 2 ul of pooled liquid hemolymph was diluted with 8 ul TBS (5mM Tris pH 6.6, 
137mM NaCl and 2.7mM KCl in water) on ice then incubated at 70 degree for 5 min 
before clarification by centrifugation at 20 Kg for 1 min. After that, 4-6 ul of the 
supernatant was taken out for free glucose measurement. The rest supernatant was 
added with 1 ul of trehalase (~5 ug, Sigma T8778) and incubated overnight at 37 
degree. On the second day, 500 ul assay reagent was added to both glucose and 
trehalose samples while another 500 ul assay reagent was added to the same amount 
of TBS as blank controls. After 30 min incubation at 37 degree, all the reactions were 
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stopped by adding 500 ul of 12 N H2SO4, and OD 540nm was measured in TECAN 
M200 Pro microplate reader. 
 
5.10 Triglyceride and Glycogen assay 
Materials:  
Triglyceride kit (Sigma T2449): 
1 volume of Triglyceride regent was mixed with 4 volumes of free glycerol reagent to 
make triglyceride assay solution. 
Glycogen assay kit (Bio Vision K646-100): 
46 ul Development buffer, 2 ul Development Enzyme mixture and 2 ul OxiRed probe 
were mixed to get 50 ul Reaction Mix for each sample.  
Quick Start Bradford Protein assay (Bio-Rad): 
1X dye reagent (#500-0205) was warmed to ambient temperature before use. 
Methods:  
Controlled growth conditions were also used here. Tm6 Tb balancers were used to 
allow genotyping at 2nd instar larvae stage. Later, 10 wandering stage 3rd instar larvae 
per vial were collected (3 sets per measurement), and kept on ice for immediate 
experiment, or at -80 degree for storage (on dry ice till homogenization). Samples 
were homogenized in 800 ul buffer (5 ul of 10% Tween-20 in 1 ml water) using 
Sartorius Potter-S tissue homogenizer for 60 sec with ~30 movements. After 5 min of 
heat inactivation at 70 degree and centrifugation at 14000 rpm for 3 min, 20 ul 
supernatant was taken out for triglyceride measurement to incubate with 180 ul 
triglyceride assay solution at 37 degree for 10 min. Meanwhile another 3 ul 
supernatant was taken out and adjusted to 50 ul with hydrolysis buffer (Bio Vision 
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K646-100) for glycogen measurement: each sample was mixed with 2 ul hydrolysis 
enzyme mixture for 30 min at room temperature before 50 ul Reaction Mix was added 
and incubated in dark at room temperature for another 30 min. Finally, 10 ul 
supernatant was taken out and mixed with 200 ul 1X dye reagent (#500-0205) for 
protein estimation. In the TECAN reader, colorimetric analysis was performed at 504 
nm for triglyceride content, 570 nm for glycogen and 595 nm for protein. All data 
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Table 2 Primers for in vitro dsRNA synthesis. 
Target  CG Number Primer Name Primer Sequence 
KSR CG2899 KSR-F ACATTAATACGACTCACTATAGGGAGAGCCTGCATGAACCCACCATA 
  KSR-R ACATTAATACGACTCACTATAGGGAGAGCTTCATCCCACGGCCAACCTG 
PI3K/Dp110 CG4141 CG4141F TTATTAATACGACTCACTATAGGGAGATTCGGCATCCTCAGCCTCGGCGAG 
  CG4141R CCATTAATACGACTCACTATAGGGAGAAGGAACTGATCAGGGGATAGTC 
EGFP2 (GFP control) dsEGFPT7-up CTAATACGACTCACTATAGGGAGAGGAGCTGTTCACCGGGG 
  dsEGFPT7-low CTAATACGACTCACTATAGGGAGTCGCGCTTCTCGTTGGGG 
D-MEK/Dsor CG15793 Dsor1B(F) CACTTAATACGACTCACTATAGGGAGAGTAAACGAACCGCCGCCCAAG 
  Dsor1B(R) CACTTAATACGACTCACTATAGGGAGAGCCCAGCGTCAACGCTCTATTG 
Raf CG2845 Raf1-F ACATTAATACGACTCACTATAGGGAGAAGCCACCATCTTCATCCTCCGGCA 
  Raf1-R ACATTAATACGACTCACTATAGGGAGAACGGCCACGGGACCGTGCCAA 
  Raf2-F ACATTAATACGACTCACTATAGGGAGAGCAACTAACGCCGGATATGTG 
  Raf2-R ACATTAATACGACTCACTATAGGGAGAGCTGCTCATATTGAAGCGGA 
GAP1 CG6721 dsGAP1-f CACTTAATACGACTCACTATAGGGAGAGGCAAAGAATCTGAGCAGTC 
  dsGAP1-r CACTTAATACGACTCACTATAGGGAGATCAGTTCACTGTTCTCCTTG 
  dsGAP2-f CACTTAATACGACTCACTATAGGGAGAGATTGTCTGGACTGCACTAC 
  dsGAP2-r CACTTAATACGACTCACTATAGGGAGACCGTGCAGAACTTCTTGTAC 
pnt CG17077 17077-f CACTTAATACGACTCACTATAGGGAGAGTGGAAGCACCGGAAACAGC 
  17077-r CACTTAATACGACTCACTATAGGGAGAGAATTCCCCAACGACGAGCCA 
  pntp1-f CACTTAATACGACTCACTATAGGGAGACATAGCTTTGCAGGACCATG 
  pntp1-r CACTTAATACGACTCACTATAGGGAGAATGCATTTACTGACAGTGCA 
  pntp2-f CACTTAATACGACTCACTATAGGGAGAGCAAGGTCAACGAGGTACTG 
  pntp2-r CACTTAATACGACTCACTATAGGGAGACCGACGTCACATAATCCATG 
PVR CG8222 dsPVR1-f CACTTAATACGACTCACTATAGGGAGAATGGAATGGTTCACTCCGTC 
  dsPVR1-r CACTTAATACGACTCACTATAGGGAGAATCACACTGACGTTGTACTC 
  dsPVR2-f CACTTAATACGACTCACTATAGGGAGATCGGTTCACATTGAGACCAG 
  dsPVR2-r CACTTAATACGACTCACTATAGGGAGACAGACCGATCAGGATGAGGA 
yan CG3166 3166-f CACTTAATACGACTCACTATAGGGAGAGCTCCCAGTACAGTTATCATTG 
  3166-r CACTTAATACGACTCACTATAGGGAGACCAGACTGTGAGCAGAACTG 
Sin3A CG8815 8815-f CACTTAATACGACTCACTATAGGGAGATTTGGGTGCAACGACTCTTCC 
  8815-r CACTTAATACGACTCACTATAGGGAGAAGCGAATTGTCCGAAATGTGC 
lilli CG8817 8817-f CACTTAATACGACTCACTATAGGGAGACGTCCAGCGTCACAAACAATG 
  8817-r CACTTAATACGACTCACTATAGGGAGAATCGTCCCACTTGTTGCTCC 
bowl CG10021 10021-f CACTTAATACGACTCACTATAGGGAGACGACGAGGAGGATTCGTTGC 
  10021-r CACTTAATACGACTCACTATAGGGAGACCCAGGTGGTACAGAATATCG 
NFAT CG11172 11172-f CACTTAATACGACTCACTATAGGGAGACACCAATTCCACAATGAGTG 
  11172-r CACTTAATACGACTCACTATAGGGAGAGGTGAATGTTGTTGCTGCTG 
spen CG18497 18497-f CACTTAATACGACTCACTATAGGGAGACACCGTTAATTCTGTCACAG 
  18497-r CACTTAATACGACTCACTATAGGGAGACGATAAAGAGTGTCCTTGTC 
kay CG33956 33956-f CACTTAATACGACTCACTATAGGGAGAGTCCAAGCTGGTCAGCTTATA 
  33956-r CACTTAATACGACTCACTATAGGGAGAACGCTCCTGTTTGCTTTCTAC 
 
 
Table 3 Primers for real time PCR reaction using Sybr Green reagent.  
Target CG Number Forward Primer Reverse Primer 
Kinesin CG7765 CTTTTCATAGCGTCGCTTCC GCTAAGCTGTCGCACAAA 
rp49 CG7939 GCTAAGCTGTCGCACAAA TCCGGTGGGCAGCATGTG 
KSR CG2899 AGCCGAGCGAAGATTGTAAA TCCCGATACATGCCTACACA 
InR CG18402 CTGGTGGTGCTGACAGAGAA GCAGCTGACAACTGGCATTA 
pri-InR CG18402 CAAGAGACAGCAACAAAAGG GCTTGCATGTGTTGGTGAGC 
InR-A CG18402 CAATGCACGACAACAAAACC GGCACTCGATGATCATTTCA 
InR-B CG18402 TCGAAACGTTGAGATCGTTG CGCACTTGTATTTCGTGGAA 
InR-C CG18402 GTGCCTCGCACTTTGCTTAT ATACGCTCACCAACACATGC 
InR-D CG18402 CGTTGTTGTTGCTGCTGTTT GTCTCGTGCTCTCCTGCTCT 
Pnt/pntp1 CG17077 CGATGCGAATGCCTACTACACG TGCTGGTGTTGTAGCCTGAAC 
pntp2 CG17077 TTTCTGTCCAGCCTAGTTGAGTCG AACTGCACAGATCCTTGCATCC 
PVR CG8222 AATGACCACCGTCCCAGAAGAC CAGGCGGGTTGTACGGAGTTATTG 
 
 
